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1 Abbreviations 
ABDA Bundesvereinigung Deutscher Apothekerverbände 
(Federal organization of the German pharmacist associations) 
ACE Angiotensin-converting enzyme 
ADE Adverse drug event 
ADR Adverse drug reaction 
ATC Anatomical therapeutical chemical 
BMI Body mass index 
CD-ROM Compact disc read-only memory 
CI Confidence interval 
CPOE Computerized physician order entry 
CYP Cytochrome P450 isoenzyme 
DDI Drug-drug interaction 
DIF Drug Interaction Facts 
DR Drug-Reax 
DRP Drug-related problem 
e.g. For example 
FPH Foederatio Pharmaceutica Helvetiae 
GI Gastrointestinal 
H. pylori Helicobacter pylori 
ICD-10 International classification of diseases, 10th revision 
INR International normalized ratio 
LI Lexi-Interact 
MAO Monoamine oxidase 
n Number of patients 
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no. Number 
NPV Negative predictive value 
NRS Nutrition risk score 
NSAID Nonsteroidal antiinflammatory drug 
OATP Organic anion transporting polypeptide 
OR Odds ratio 
ORCA OpeRational ClassificAtion 
PDA Personal digital assistant 
pDDI Potential drug-drug interaction 
PPI Proton pump inhibitor 
PPV Positive predictive value 
PV Pharmavista 
SSRI Selective serotonin reuptake inhibitor 
VAT Value-added tax 
vs Versus 
WHO World Health Organization 
yr Year 
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2 Introduction 
Drug-related problems 
Besides their beneficial effects, drugs may also induce illness and death. Adverse 
drug reactions (ADRs) have been the focus in most studies on drug-induced 
morbidity, but they form only a small part of drug-related problems (DRPs). 
Medication errors, overdosage, drug dependence, non-compliance and therapeutic 
failure are further examples of DRPs [1]. Definitions of DRPs are shown in Table I, 
and the relationships between these terms are given in Figure I. 
Table I: Definitions of drug-related problems 
Drug-related problem An event or circumstance involving drug therapy that actually or 
potentially interferes with desired outcomes [2] 
Medication error Any error in the process of prescribing, dispensing or administering a 
drug, whether there are adverse consequences or not [3] 
Adverse drug reaction Any response to a drug which is noxious and unintended and which 
occurs at doses normally used in humans for prophylaxis, diagnosis or 
therapy of disease, or for the modification of physiological function, given 
that this noxious response is not due to a medication error [4] 
Adverse drug event An injury related to the use of a drug, although the causality of this 
relationship may not be proven [3] 
 
Medication errors are defined as problems that involve a mistake in the process from 
the prescribing to the administration of the drug [3]. Problems that occur even when 
no errors have been made in the process of drug distribution are called ADRs [4]. 
Adverse drug events (ADEs) are defined as problems related to the use of a drug, 
but without evidence of the causality [3]. 
Despite these definitions, the term “ADR” is used in the literature (e.g. Krahenbuhl-
Melcher et al. [5]) – and also in our studies – as a more general term. Consequently, 
DRPs due to medication errors such as drug-drug interactions (DDIs) are included in 
the definition of an ADR. 
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Figure I: Relationship between the terms medication errors, adverse drug reactions and adverse drug 
events (according to Krahenbuhl-Melcher et al. [5]) 
 
Drug-induced morbidity has become a common problem and contributes to a large 
economic burden for society [6-11]. Classen et al. reported that ADEs significantly 
prolong the length of hospital stay, increase the costs of treatment, and elevate the 
risk of death almost two-fold [6]. Some studies suggest that medication errors or 
ADRs cause between 7’000 and 100’000 deaths annually in the United States [8, 9]. 
Lazarou et al. reported that ADRs rank between the fourth and sixth leading cause of 
death in the United States [9]. 
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Drug-related problems at hospital admission 
Hospital admissions associated with ADEs range from 0.2 to 21.7%, of which up to 
72% have been judged to be avoidable [12-18]. According to Pirmohamed et al., 
ADRs (including DDIs) were responsible for 6.5% of hospital admissions. 2.3% of 
these patients died as a direct result of the ADR [16]. The proportion of ADR-related 
hospitalizations in a national wide study in The Netherlands was 1.8% of all acute, 
non-planned hospital admissions [18]. In Switzerland, Lepori et al. showed that 6.4% 
of the patients presented an ADR at hospital admission, and 65% of these 
admissions were directly related to an ADR [11]. 
Drug-related problems during hospitalization 
During a patient’s hospital stay, the incidence of ADEs ranges between 0.7 and 
6.5%. Up to 57% of these are considered preventable [19-23]. According to Lazarou 
et al., the overall incidence of serious ADRs in hospitalized patients was 6.7% [9]. 
Among hospitalized elderly people 61% presented at least one ADR, and an average 
of 1.7 ADRs per patient was found [17]. According to an analysis of medical 
inpatients at two Swiss hospitals, in 11% of all hospitalizations clinically relevant 
ADRs occurred, and the incidence of possibly ADR-related deaths was 0.14% [22]. 
Drug-related problems at hospital discharge 
Changes in medication at the transition point from outpatient to inpatient care and 
vice versa may increase the frequency of DRPs [24, 25]. Drug modifications shortly 
before hospital discharge may be important in this context, because the monitoring of 
patients significantly declines after hospital discharge [26, 27]. According to Forster 
et al., 11% of discharged patients developed an ADE within 24 days. 27% of them 
were preventable. One out of seven injuries was rated as life-threatening [27]. 
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Medication errors 
The most common type of avoidable errors during the medication process are 
prescribing errors [21, 28-30]. According to Bates et al., preventable ADEs occurred 
mostly at prescribing (56%) and at drug administration (34%), while transcription and 
dispensing errors occurred at a rate of 6% and 4%, respectively [21]. An investigation 
on the incidence and clinical significance of prescribing errors in inpatients showed 
that 54% of prescribing errors were associated with the dosing, and that 61% 
originated in medication order writing [31]. However, when only serious errors were 
examined, 58% originated in the prescribing decision [31]. 
Dean at al. analyzed the reasons of prescribing errors and showed that most 
mistakes were due to slips in attention, or to prescribers omitting relevant rules. 
Physicians identified risk factors such as work environment, workload, whether they 
are prescribing for their own patient, communication within their team, physical and 
mental well-being, and lack of knowledge. System factors, such as inadequate 
training, low perceived importance of prescribing, a hierarchical structure of the 
medical team, and absence of self-awareness were also identified. [32] 
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Drug-drug interactions 
DDIs occur when the effect of one drug is changed by the presence of another drug. 
The outcome can be harmful if the DDI causes an increased toxicity of the drug. 
However, a reduction in therapeutic efficacy due to a DDI may be just as harmful as 
an increase. For instance, an unintended decrease in anticoagulation by oral 
anticoagulants is observed when combined with an inducing agent. While such a DDI 
is unwanted, others can be beneficial and valuable, for instance the co-prescription of 
antihypertensive drugs and diuretics in order to achieve a better antihypertensive 
effect. [33] 
Epidemiological data relating to the negative clinical outcome of DDIs are rare and 
therefore we use the expression potential (p)DDI. Hamilton et al. pointed out that 
exposure to pDDIs was associated with a significantly increased risk of 
hospitalization [34]. According to Pirmohamed et al., one percent of all hospital 
admissions was caused by DDIs, corresponding to 16% of all patients admitted with 
ADRs (including DDIs) [16]. In a recent review, an incidence of up to 2.8% of hospital 
admissions were found to be caused by ADRs due to DDIs [35]. Lepori et al. showed 
that 21% of all drug-related hospital admissions in a Swiss hospital were caused by 
DDIs (1.3% of all admissions) [11]. 
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3 Aims of the Thesis 
The general aim of this thesis was to elucidate the importance of potential drug-drug 
interactions (pDDIs) as a contributing factor in drug safety issues. 
The first focus of this thesis was an evaluation study of frequently used drug 
interaction screening programs. The specific objective of this study was to critically 
appraise these programs regarding their possible implementation in the Medical 
Department of the Cantonal Hospital of Baden. 
The second focus of this thesis was to identify clinically relevant pDDIs in the Medical 
Department of the Cantonal Hospital of Baden, with the goal of improving the clinical 
management of pDDIs by pharmacist interventions during hospitalization and at 
hospital discharge. 
The third focus of this thesis was to investigate risk factors for gastrointestinal 
bleeding possibly leading to hospital admission and to assess the role of pDDIs as a 
cause of this adverse drug reaction. 
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4 Methods, Results and Discussion 
The content of this dissertation is the subject of four publications. Thus, the following 
pages contain these papers starting with the evaluation of drug interaction screening 
programs, continuing with the prevalence of drug-drug interactions during 
hospitalization and the pharmacist intervention study and ending with a case-control 
study about risk factors for gastrointestinal bleeding. 
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Abstract 
Introduction 
Drug interaction screening programs are an important tool to check prescriptions of 
multiple drugs for potential drug-drug interactions (pDDIs). Several programs are 
available on the market. They differ in layout, update frequency, search functions, 
content and price. The aim of the current study was to critically appraise several 
interaction screening programs in the Department of Medicine of a Swiss public 
teaching hospital. 
Methods 
A drug interaction screening program had to fulfil minimal requirements (information 
on effect, severity rating, clinical management, mechanism and literature) in order to 
be admitted to the present evaluation. The 100 most frequently used drugs in the 
Cantonal Hospital of Baden, Switzerland, were used to test the comprehensiveness 
of the programs. Qualitative criteria were used for the assessment of the drug 
interaction monographs. In a precision analysis, 30 drugs with and 30 drugs without 
pDDIs of clinical importance were tested. In addition, 16 typical patient profiles were 
checked for pDDIs, using Stockley’s Drug Interactions as a reference. 
Results 
Out of nine programs included, the following four fulfilled the above mentioned 
criteria: Drug Interaction Facts, Drug-Reax, Lexi-Interact and Pharmavista. Drug 
Interaction Facts contained the lowest number of drugs and was therefore the least 
qualified program. Lexi-Interact condenses many DDIs into one group, resulting in 
less specific information, whereas Pharmavista and Drug-Reax offer excellent 
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interaction monographs. In the precision analysis, Lexi-Interact showed the best 
sensitivity (1.00), followed by Drug-Reax and Pharmavista (0.83 each) and Drug 
Interaction Facts (0.63). The analysis of patient profiles revealed that out of 157 
pDDIs found by all programs, only 18 (11%) were detected by all of them. No 
program found more than 50% of the total number of pDDIs. A further evaluation 
using Stockley’s Drug Interactions as the gold standard revealed that Pharmavista 
achieved a sensitivity of 0.86 (versus Drug Interaction Facts, Lexi-Interact and  
Drug-Reax with a sensitivity of 0.71 each) with an acceptable positive predictive 
value of 0.67. 
Conclusion 
In order to detect most pDDIs without causing too many false positive results, drug 
interaction screening programs should have a high sensitivity and a high positive 
predictive value. Pharmavista offers the highest sensitivity of the programs evaluated 
with a positive predictive value in an acceptable range. An increase in sensitivity is 
possible by the combination of two programs. 
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Introduction 
Adverse drug reactions are associated with considerable morbidity and mortality  
[1, 2]. For instance, they are responsible for up to 5% of hospital admissions. 
According to a recently published study one percent of all hospital admissions were 
caused by drug-drug interactions (DDIs), corresponding to 16% of all patients 
admitted with adverse drug reactions [3]. In fact, the clinical outcome of a potential 
(p)DDI is often unknown, and epidemiological data are rare. Juurlink et al. calculated 
odds ratios of 6.6 for hypoglycaemia in patients treated with glyburide in combination 
with co-trimoxazole, 11.7 for digoxin toxicity in patients treated with clarithromycin 
and 20.3 for hyperkalaemia in patients with angiotensin-converting enzyme inhibitors 
combined with potassium-sparing diuretics [4]. 
In order to reduce the number and to improve the management of pDDIs, physicians 
primarily have to be aware of the presence of a pDDI. Recommendations include 
different books, tables and consultation of the primary literature. An automatically 
applied drug interaction screening program would be highly desirable and timesaving 
for the drug prescription. 
Different studies evaluating such programs have been conducted and published 
before [5-8]. Hazlet et al. focused on the precision analysis of nine non identified drug 
interaction screening programs. Sensitivity, specificity, positive (PPV) and negative 
predictive value (NPV) were determined by the analysis of 16 pDDIs contained within 
six patient profiles [6]. Jankel and Martin evaluated six widely used drug interaction 
screening programs according to criteria developed by a panel of seven pharmacists. 
The panel determined that a drug interaction screening program should be user 
friendly and efficient, provide guidance in making a decision to intervene and be 
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relevant to the user’s practice. Additional criteria fell into three categories: knowledge 
base, presentation of the information as well as hardware and software attributes. 
None of the six evaluated programs was considered to be ideal by the panel [5]. 
Barla et al. listed nine criteria to test the scientific quality of drug interaction screening 
programs. Drug pairs with or without interactions have been selected for each of 
these criteria and have been used for the evaluation of eight programs. None of 
these programs was considered to be satisfactory [9]. Barrons studied the accuracy, 
comprehensiveness and user friendliness of nine drug interaction screening 
programs running on personal digital assistants (PDA). Accuracy was scored by the 
summation of software sensitivity, specificity, PPV and NPV. The comprehensive-
ness of each program was determined by the number of components provided in the 
drug interaction monograph. The time to find out the management of five important 
pDDIs defined each program’s ease of use. The aggregate scores for accuracy, 
comprehensiveness and ease of use were calculated [7]. Perrin et al. evaluated 
seven drug interaction screening programs on the basis of 60 common pDDIs in 
hospitalized patients, 40 pDDIs in ambulatory patients, 10 classical and well-known 
pDDIs and 10 recently discovered pDDIs. In addition to the detection of the 
mentioned pDDIs, the program’s assessment included information on the severity, 
the mechanism, the symptoms, the clinical management of the pDDIs and on the 
references provided. Update frequency, language, price, installation, print-out of the 
summary, user friendliness and connections to the patient’s record were also 
decisive criteria [8]. 
None of the mentioned evaluation studies fulfilled our requirements, however. Two 
studies [5, 9] were conducted in 1992 and were judged not to be actual. One 
evaluation did not mention the program’s names [6] and Barrons study [7] focused on 
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PDA programs only. The latest study [8] was published when the present evaluation 
was in progress and is going to be discussed at the end of this evaluation. 
The specific aim of our study was to critically appraise frequently used drug 
interaction screening programs regarding a possible implementation in the 
Department of Medicine of a Swiss public teaching hospital. 
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Methods 
Inclusion criteria 
Nine different computerized drug interaction screening programs (British National 
Formulary, Drug Interaction Facts, Drug-Reax, ePocrates MultiCheck, Lexi-Interact, 
Pharmavista, Stockley’s Drug Interactions, The Medical Letter and Vidal) were 
initially included in our evaluation. In order to be admitted to the final evaluation (see 
below), an interaction screening program had to fulfil several minimal requirements: 
information in the interaction monographs on the effect (pharmacokinetic and/or 
pharmacodynamic) of a specific pDDI, on the clinical management and on the 
mechanism of the pDDI and about the references provided regarding this pDDI. 
Furthermore, a severity rating was required. 
Only four out of the nine drug interaction screening programs included fulfilled all of 
these criteria and were chosen for the additional studies as detailed below. 
Qualitative assessment of the drug interaction monographs 
To assess the quality of the drug interaction monographs, eight pDDIs were analyzed 
with each program: carbamazepine - acetaminophen, lamotrigine - valproic acid, 
indinavir - St. John’s wort, simvastatin - voriconazole, aspirin - enalapril, potassium 
chloride - spironolactone, isosorbide dinitrate - sildenafil and dihydroergotamine - 
sumatriptan. All of these pDDIs were classified as major or moderate by any of the 
inspected drug interaction screening programs. 
Different questions had to be answered: How useful is the information on the effect, 
the clinical management and the mechanism of the pDDI? How complete is the 
literature provided? Do programs perform drug grouping according to their 
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therapeutical group and/or pharmacokinetics? And if so, is the categorisation useful? 
Are there other ratings than those about the severity of the adverse reaction? Does a 
documentation rating exist? Is there information about the onset of the effect? Is 
there a standardization concerning the severity rating, the documentation rating and 
the onset of the effect? Is the content of the monographs supported by the literature 
cited? If a question could not be answered with the available information, the editors 
of the program were contacted. 
Comprehensiveness of the drug lists in the interaction screening programs 
In this part of the final evaluation, we investigated the completeness of the drug 
interaction screening programs concerning drugs. Programs were screened for the 
100 most frequently prescribed drugs in the Department of Medicine of the Cantonal 
Hospital of Baden, Switzerland, in 2003. The frequency of the drug prescriptions was 
calculated as therapeutical days using the Defined Daily Dose as defined by the 
WHO [10]. If a drug name was not found by the drug interaction screening program, 
other nomenclatures – not familiar for European users – were tested using the 
Martindale [11]. 
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Precision analysis 
The performance of the drug interaction screening programs was assessed for 
sensitivityi, specificityii, PPViii and NPViv. Sensitivity was defined as the ability of the 
drug interaction screening program to correctly identify pDDIs that were clinically 
important. Specificity was defined as the ability of the drug interaction screening 
program to ignore interactions that were clinically unimportant. The PPV indicated the 
probability that, when the drug interaction screening program identified a pDDI, it was 
a pDDI defined as clinically important. The NPV indicated the probability that a pDDI 
was defined as clinically unimportant, if the drug interaction screening program 
ignored the pDDI. [12] 
A total of 60 drug pairs (Table I) were selected using the hard copy of Stockley’s 
Drug Interactions [13], which was defined as the gold standard. Thirty drug pairs 
were labelled as clinical important (Stockley defined the interaction as clinically 
important and/or a monitoring was required), and 30 pairs were labelled as clinically 
unimportant (Stockley defined the interaction as clinically unimportant and/or no 
                                                 
i Sensitivity: The ability to detect clinically important interactions. Sensitivity = number of true-positives 
/ (number of true-positives + number of false-negatives) 
ii Specificity: The ability to ignore clinically unimportant interactions. Specificity = number of true-
negatives / (number of true-negatives + number of false-positives) 
iii Positive predictive value (PPV): When a drug interaction is found, the probability that the interaction 
is clinically important. PPV = number of true-positives / (number of true-positives + number of false-
positives) 
iv Negative predictive value (NPV): When a drug interaction is ignored, the probability that the 
interaction is clinically unimportant. NPV = number of true-negatives / (number of true-negatives + 
number of false-negatives) 
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effect was observed). Furthermore, all of the inspected drugs had to be included in 
every drug interaction screening program evaluated. 
Table I: Drug pairs included in the precison analysis. Thirty clinically important and 30 clinically 
unimportant potential drug-drug interactions were chosen using Stockley’s Drug Interactions as a 
reference. 
clinically important interactions  clinically unimportant interactions 
   
alprazolam - digoxin  acyclovir - cyclosporine 
amiodarone - clarithromycin  allopurinol - atenolol 
antacids/iron - levofloxacin  allopurinol - digoxin 
captopril - lithium  aspirin - digoxin 
carbamazepine - felodipine  atenolol - eletriptan 
chlorpromazine - haloperidol  azithromycin - triazolam 
cimetidine - vardenafil  busulfan - fluconazole 
ciprofloxacin - theophylline  candesartan - digoxin 
cisplatin - gentamicin  cefotaxime - ofloxacin 
clarithromycin - triazolam  ciprofloxacin - oral contraceptive 
clindamycin - gentamicin  clonidine - maprotiline 
clonidine - imipramine  caffeine - grapefruit juice 
clozapine - fluvoxamine  co-trimoxazole - indinavir 
cyclosporine - enalapril  dexamethasone - theophylline 
desipramine - ritonavir  didanosine - fluconazole 
dexamethasone - itraconazole  diltiazem - pravastatin 
digoxin - diltiazem  doxorubicin - tamoxifen 
digoxin - telmisartan  enalapril - sildenafil 
dihydroergotamine - eletriptan  ethinylestradiol - orlistat 
diltiazem - lovastatin  flurazepam - warfarin 
diltiazem - rifampicin  gentamicin - lincomycin 
disulfiram - metronidazole  grapefruit juice - pravastatin 
droperidol - sotalol  haloperidol - valproic acid 
ergotamine - erythromycin  imipramine - olanzapine 
felodipine - itraconazole  lidocaine - verapamil 
furosemide - indometacin  lithium - olanzapine 
ganciclovir - lamivudine  methotrexate - tacrolimus 
moxifloxacin - thioridazine  metronidazole - sucralfate 
orale contraceptive - rifampicin  metronidazole - sulfasalazine 
penicillin - probenecid  ofloxacin - theophylline 
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If a program detected a specific DDI, which was not listed by Stockley, the literature 
cited by the program was checked concerning the year of publication. If the 
references cited were between 2002 and 2004, they had to be reassessed, because 
the last edition of Stockley was published in 2002. The clinical relevance of such 
DDIs was judged by a clinical pharmacist and by a physician. 
Patient profiles 
This final part of the study evaluated the clinical practicability of the programs. 
Sixteen patients with different diagnoses were chosen and their drug lists were 
analyzed for pDDIs. Potential DDIs were arranged regarding the severity rating 
(major, moderate or minor). For Pharmavista, the lowest three levels of five severity 
ratings were condensed into one to simplify the levels. 
The clinically relevant DDIs identified were then compared with Stockley’s Drug 
Interactions [13], which was again used as the gold standard. Sensitivity, specificity, 
PPV and NPV were calculated for each program, identically as described above for 
the precision analysis. If a drug was not included in Stockley, the corresponding drug 
pairs were excluded from the analysis. DDIs detected by the programs but not listed 
in Stockley were considered to be false positive results. If such DDIs had been 
published after the year 2001, they were reassessed. If they were considered to be 
clinically important, they were accepted as a positive result. Otherwise, they were 
considered as a false positive result. 
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Results 
Four drug interaction screening programs (Drug Interaction Facts (DIF), Drug-Reax 
(DR), Lexi-Interact (LI) and Pharmavista (PV)) fulfilled the mentioned inclusion 
criteria. These programs are described in more detail in Table II. In all of these 
programs, the interaction monographs are divided into different chapters for severity, 
effects, mechanism, clinical management, discussion (or summary) and literature. As 
an exception, in LI the effect and the mechanism are provided in a common chapter 
called summary. 
Table II: Characterisation of the drug interaction screening programs included in the final analysis 
Program / Homepage Editor / 
Data source 
Version Update 
frequency 
Pricea) Version used in 
this study / Date 
      
online monthly $ 473b) 
CD-ROM every 3 months $ 199 
Drug Interaction Facts 
http://www.factsandcom 
parisons.com 
Tatro DS / 
eFacts / Facts 
& Comparisons PDA every 3 months $ 69 
online 
Mars - June 2004 
online every 3 months € 695 
CD-ROM every 3 months € 634 
Drug-Reax 
http://www.micromedex.com 
Thomson 
MICROMEDEX 
PDA every 3 months € 99 
CD-ROM 
Vol. 119, 120, 121 
online daily $ 425c) 
CD-ROM monthly $ 475d) Lexi-Interact 
http://www.lexi.com 
Lexi-Comp 
PDA monthly $ 75 
online 
Mars - June 2004 
online monthly 
CD-ROM monthly 
CHF 650e) Pharmavista 
http://www.pharmavista.ch 
e-Mediat AG / 
ABDA-
Datenbank 
PDA every 3 months CHF 120 
online 
Mars - June 2004 
a) Prices for a subscription for one year, single user, exclusive VAT, August 2005 
b) Price for the whole database eFacts, interaction module not available separately 
c) Price for Lexi-Comp OnLine (13 databases), inclusive Lexi-Comp Complete PDA-version 
(15 databases), Lexi-Interact not available separately 
d) Price for Lexi-Comp Complete (15 databases), inclusive online and PDA-version, Lexi-Interact not 
available separately 
e) Price for the whole database Pharmavista for four users, online and CD-ROM version together, 
interaction module not available separately 
ABDA = Bundesvereinigung Deutscher Apothekerverbände (federal organization of the German 
pharmacist associations), CD-ROM = compact disc ready-only memory, PDA = personal digital 
assistant, VAT = value-added tax 
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Qualitative assessment of the drug interaction monographs 
All drug interaction screening programs offered useful information on the effect, the 
clinical management and the mechanism of the pDDI, and the literature. However, 
PV’s and DR’s monographs are of excellent quality (detailed and sophisticated) and 
were assessed as superior compared to the other two programs. As described 
above, LI does not provide a separate chapter concerning the effect and the 
mechanism of the pDDI. 
Each of the four programs sometimes concentrated similar drugs into one 
monograph, but to a different extent. DR rarely pooled more than two interacting 
drugs. The grouping of similar drugs in terms of therapeutical effects and 
pharmacokinetics by DIF and PV was considered to be user-friendly (e.g. potassium 
salts - potassium-sparing diuretics or nitrates - phosphodiesterase-5 inhibitors). 
However in LI, the condensation of individual drugs into drug classes was done in an 
excessive manner. This concept therefore resulted in less specific information within 
the monograph of a specific drug. For example, the interaction between simvastatin 
and voriconazole appeared in the monograph CYP3A4 substrates - CYP3A4 
inhibitors (moderate), and no information about increased simvastatin plasma 
concentrations and possible rhabdomyolysis or about alternative drugs like 
pravastatin or fluvastatin were given. The same problem occurred regarding the pDDI 
between dihydroergotamine and sumatriptan, which was displayed in the monograph 
Serotonin Modulators - Serotonin Modulators together with another 50 drugs called 
Serotonin Modulators. As a consequence, no precise information on the effect and 
the clinical management of individual pDDIs were available. 
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In addition to the severity rating, LI offered a classification called risk rating, where 
not only the severity, but also the clinical management is taken into account. DIF 
provided a second classification as well. The so-called significance level represents a 
mixture between the rating of the severity and the documentation of the pDDI in the 
literature. Documentation ratings were provided by all four programs evaluated. 
The onset of the effect was mentioned separately in the monographs of DIF and DR 
and sometimes also in LI. No separate chapter existed in PV, but the onset of the 
effect was usually mentioned in the description of the effect. 
Severity ratings (as well as the risk rating and the significance level), documentation 
ratings and information on the onset of the effect were standardized by each 
program. 
Citations in DIF, DR and LI were clearly linked with the corresponding literature. 
Regrettably, in PV the references were not assigned to specific statements in the 
monograph. 
Comprehensiveness of the drug lists in the interaction screening programs 
Figure I shows the number of drugs not included in the drug interaction screening 
programs and the number of drugs with an unusual nomenclature for European 
users. The number of drugs not included in the respective program was highest for 
DIF (25% of all drugs tested) and lowest for LI (3% of all drugs tested). To give some 
examples for an unusual nomenclature in Europe: acetaminophen instead of 
paracetamol, albuterol instead of salbutamol or torsemide instead of torasemide. 
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Figure I: Comprehensiveness of the drug interaction screening programs regarding the drugs 
included. The programs were tested for the comprehensiveness of their drug lists by checking the 100 
drugs used most often on the medical wards of the Cantonal Hospital of Baden, Switzerland, in the 
year 2003. The figure shows the number of drugs not recognized by the drug interaction screening 
programs and the number of drugs with an unusual nomenclature for European users. 
DIF = Drug Interaction Facts 
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Precision analysis 
LI showed the best sensitivity, followed by DR and PV (Table III). Both DR and PV 
failed to detect five DDIs, whereas DIF found only two thirds of clinically important 
pDDIs. 
Table III: Results of the precison analysis. Thirty clinically important and 30 clinically unimportant 
potential drug-drug interactions (see Table I) were analyzed. 
 DIF DR LI PV 
     
True positive 19 25 30 25 
False positive 0 3 6 5 
True negative 30 27 24 25 
False negative 11 5 0 5 
Sensitivity 0.63 0.83 1.00 0.83 
Specificity 1.00 0.90 0.80 0.83 
Positive predictive value 1.00 0.89 0.83 0.83 
Negative predictive value 0.73 0.84 1.00 0.83 
DIF = Drug Interaction Facts, DR = Drug-Reax, LI = Lexi-Interact, PV = Pharmavista 
 
False positive results were provided by DR (3), LI (6) and PV (5). The cited literature 
has generally been published before 2002, with four exceptions. In the monograph of 
lithium - olanzapine, DR referred to a product information of 2002 [14]. Regarding the 
drug pair theophylline - ofloxacin, PV referred to a product information of 2004 [15], 
and concerning the fluconazole - busulfan and verapamil - lidocaine interactions, LI 
referred to a recent publication of in vitro and in vivo studies [16]. These pDDIs were 
reassessed and found to be clinically unimportant. 
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Patient profiles 
The medication profiles of 16 medical patients, who were treated by a mean number 
of 15 ± 6 drugs, were analyzed. Totally, 99 different drugs were prescribed and 1'376 
different drug pairs had to be tested. As shown in Figure II, the number of pDDIs 
detected with minor and moderate severity was comparable between the programs. 
In contrast, regarding the pDDIs with major severity, the number detected by DR was 
34, whereas the other programs detected only two to four of such pDDIs. A closer 
look at the pDDIs with major severity detected by DR revealed that 18 out of the 34 
pDDIs were caused by interactions between valerian preparations and so-called 
hepatotoxic drugs. These pDDIs were not listed by the other programs. The total 
number of the pDDIs detected was 157, and the number of the pDDIs detected by all 
programs was 18. The discrepancy between these figures suggests that there are 
large differences in the pDDIs identified by the programs. 
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Figure II: Detection of potential drug-drug interactions (pDDIs) by different drug interaction screening 
programs. The drug profiles of 16 medical patients of the Cantonal Hospital of Baden, Switzerland, 
were analyzed. The patients were treated with an average number of 15 ± 6 drugs, resulting in a total 
of 1'376 different drug pairs to be analyzed. Different severities means that the pDDI is categorised 
into different severities by several programs. 
DIF = Drug Interaction Facts, Lexi-IA = Lexi-Interact; 
 
In order to perform a precision analysis with clinical relevance, Stockley’s Drug 
Interactions was used as the gold standard. Out of the 99 different drugs used by the 
patients, Stockley did not include eight, which were therefore excluded. In addition,  
26 drug pairs could not be assessed clearly for different reasons and were therefore 
also excluded. Finally, 951 drug pairs were assessed whereof 35 clinically relevant 
pDDIs were detected using Stockley. Taken together, a total of 74 additional pDDIs 
were detected by the four drug interaction screening programs. These 74 pDDIs 
were reassessed regarding their date of publication. Two of them, published after 
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2002, were found to be clinically relevant and were accepted as positive results, 
whereas the remaining 72 pDDIs were considered to be false positive results. As 
shown in Table IV, all drug interaction screening programs showed high specificities 
(≥ 0.95) and also high NPV (0.99). In comparison, the sensitivities were lower  
(0.71 - 0.86), as well as the PPV (ranging from 0.36 for LI to 0.69 for DIF). 
Table IV: Analysis of patient profiles. Drug profiles of 16 patients from the Cantonal Hospital of Baden, 
Switzerland, were analyzed for potential drug-drug interactions. The patients were treated with 15 ± 6 
drugs, resulting in a total of 1’376 different drug pairs. Of these, 951 could finally be analyzed. For 
most of the drug pairs excluded, one of the drugs was not listed in Stockley’s Drug Interactions, which 
was used as the reference. 
 DIF DR LI PV 
     
True positive 25 25 25 30 
False positive 11 16 46 15 
True negative 905 900 870 901 
False negative 10 10 10 5 
Sensitivity 0.71 0.71 0.71 0.86 
Specificity 0.99 0.98 0.95 0.98 
Positive predictive value 0.69 0.61 0.36 0.67 
Negative predictive value 0.99 0.99 0.99 0.99 
DIF = Drug Interaction Facts, DR = Drug-Reax, LI = Lexi-Interact, PV = Pharmavista 
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Discussion 
Drug interaction screening programs vary in price, update frequencies, search and 
filter functions, and in the information within the interaction monographs. The 
comparison of prices is of limited usefulness, however, because different packages 
are included and drug interaction screening programs are often not available 
separated from other programs. The information provided within the interaction 
monographs ranges from a short comment on the effect and the clinical management 
to detailed descriptions regarding the effect and its onset, the severity, the 
mechanism, the clinical management, documentation rating, discussion and 
literature. 
Unavailable severity rating (ePocrates MultiCheck, Stockley’s Drug Interactions and 
The Medical Letter), non existing description of the mechanism (British National 
Formulary and ePocrates MultiCheck) and lacking declaration of literature (British 
National Formulary, ePocrates MultiCheck and Vidal) were reasons for not fulfilling 
the inclusion criteria. Thus, only four drug interaction screening programs (DIF, DR, 
LI and PV) could be included into the final evaluation. 
Qualitative assessment of the drug interaction monographs 
The condensation of different drugs into one drug interaction monograph appears to 
be acceptable, if the same type of pDDI is documented or can be expected, and if the 
clinical management is identical. In DIF and PV, the grouping of drugs was done to a 
reasonable extent, whereas DR rarely condensed drugs into groups. In contrast, LI 
partially condensed drugs into large groups, reducing the information about individual 
pDDIs and making it difficult to identify individual drugs. Concerning LI, the drug 
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groups formed were often too large and more drug-specific information would be 
desirable. 
Concerning the severity rating, more than three levels (e.g. major, moderate, minor) 
do not appear to be clinically meaningful. A significance level (DIF), which combines 
the severity of a pDDI with its documentation, may not be helpful or may even be 
misleading. The criteria for level four (the second lowest level) in DIF are as follows: 
Interaction may cause moderate-to-major effects; data are very limited. Even if the 
documentation is scarce, severe complications may develop. However, on this level, 
the user may tend not to consider such a DDI to be potentially serious. 
On the other hand, the risk rating concept offered by LI appears to be an interesting 
approach. The risk rating is based on the OpeRational ClassificAtion (ORCA) system 
[17]. The ORCA system takes into account the potential severity of the adverse drug 
reaction due to the pDDI, the factors known to increase or decrease the risk for an 
adverse drug reaction and the existing management alternatives to avoid the pDDI or 
to reduce the risk for an adverse drug reaction by other means. 
Comprehensiveness of the drug lists in the interaction screening programs 
Regarding the comprehensiveness of the drug lists covered by the programs, DIF 
found only three quarters out of the 100 most frequently prescribed drugs in the 
Medical Clinic of a Cantonal Hospital in Switzerland. On the other hand, LI missed 
only three out of the 100 drugs tested, out of which two are not registered in the 
United States (metamizol and phenprocoumon) [18] and one is probably unimportant 
concerning pDDIs (fig sirup). PV, the only European program, surprisingly missed  
16 drugs. However, also in this case, the missed drugs were mostly considered not 
to be important regarding clinically relevant pDDIs. On the other hand, the confidence 
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of the user into the program will decrease, when drugs are frequently not included, 
even if the pDDIs associated with these drugs are of only minor clinical importance. 
Precision analysis 
A good drug interaction screening program should be able to detect clinically 
important pDDIs (high sensitivity). Regarding safety, false negative results (not 
detected pDDIs) are clinically more important than false positive results. 
Nevertheless, if the PPV is too low, there will be many unnecessary alerts, which 
may discourage the user, who may therefore miss clinically important pDDIs [19-21]. 
In our precision analysis, LI showed the best sensitivity (1.00), followed by DR and 
PV (0.83 each) and DIF (0.63). These values compare well with other studies, which 
revealed sensitivities from 0.87 to 1.00 [7] and from 0.44 to 0.88 [6]. 
The selection of the drug pairs in the study of Barrons [7] needs to be appraised 
critically. In this study, three programs were chosen as a reference, whereof two 
originated from the same editor as the evaluated PDA programs (iFacts - DIF and 
Mobile Micromedex - DR). The PDA programs were therefore assessed on the basis 
of their own full versions. As a consequence, regarding sensitivity, iFacts and Mobile 
Micromedex may have performed better in Barron’s evaluation than in our study (the 
sensitivities were 0.98 vs 0.63 for DIF and 0.95 vs 0.83 for DR in Barron’s vs our 
study). In order to avoid such biases, we used Stockley’s Drug Interactions [13] as a 
reference in our study. 
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Patient profiles 
The analysis of the patient profiles included an assessment of the pDDIs identified by 
each program and a comparison with Stockley’s Drug Interactions, which was again 
used as a reference. 
Taken together, the programs identified a total of 157 pDDIs within the 1’376 drug 
pairs examined, whereby none of the drug interaction screening programs detected 
more then a half of the pDDIs. Only 18 of these pDDIs (11% of the total) were 
detected by all programs. The number of drugs not included in the programs (DIF 19, 
DR 8, LI 8 and PV 10) cannot fully explain these findings. The interaction between 
valerian and hepatotoxic drugs, which revealed 18 potentially severe DDIs only listed 
in DR, offers an additional explanation for this discrepancy between the programs. 
The clinical significance of these interactions can be questioned, however. In the 
referenced study [22], four cases with liver toxicity related to the use of an herbal 
product containing valerian and skullcap are presented. The authors of this study 
concluded that valerian should not be combined with other herbs with the potential to 
cause hepatotoxicity. A review of the literature [23-31] revealed no information about 
hepatotoxic effects of valerian or about an increased risk for hepatotoxicity when 
valerian is combined with hepatotoxic drugs. Inclusion of pDDIs with questionable 
clinical significance offers therefore an additional explanation for the observed 
differences between the drug interaction screening programs tested. 
When the patient profiles were analyzed with Stockley as a reference, the programs 
did not differ much in their sensitivity (range 0.71 - 0.86) or NPV (0.99), but in the 
PPV (range 0.36 - 0.67). The lowest PPV was found for LI, which achieved its 
sensitivity (0.71) on the cost of a low PPV (0.36). In other words, the probability that a 
pDDI detected by LI is clinically important equals only 36%, a value appearing to be 
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too low. In comparison to the precision analysis, the results from the analysis of the 
patient profiles were not always matching. For example, LI achieved good results in 
the precision analysis (sensitivity 1.00, PPV 0.83), but scored quite badly regarding 
the patient profiles (sensitivity 0.71, PPV 0.36). In contrast, PV (0.86 vs 0.83) and 
DIF (0.71 vs 0.63) performed better with regard to sensitivity in the analysis of the 
patient profiles as compared to the precision analysis. Possibilities to explain these 
discrepancies include the number of drug pairs analyzed, the ratio between drug 
pairs with and without interaction (1:1 in the precision analysis and 35:916 in the 
analysis of the patient profiles), and the drugs analyzed. The patient profiles offer a 
better reflection of the real situation than the drugs chosen in the precision analysis. 
Comparison of the current with other studies 
Perrin et al. [8] evaluated seven drug interaction screening programs on the basis of 
60 common pDDIs observed in hospitalized patients, 40 pDDIs in ambulant patients, 
10 classic and well-known pDDIs and 10 only recently established pDDIs. 
Regrettably, the authors gave no information about the reference used for 
comparison. According to this study, Thériaque, The Medical Letter and DR showed 
the best performance. The authors also noticed that PV could be the best drug 
interaction screening program, if it detected more pDDIs (problem of low sensitivity). 
Unfortunately, PV does not link well drug names in German, potentially leading to 
false negative results. If the user enters trade names or the Latin denomination, 
much more pDDIs can be detected. 
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Conclusion 
In order to detect clinically important pDDIs within a reasonable time, we propose to 
use a program with a high sensitivity, a high NPV and an acceptable PPV. Among 
the programs tested, PV offers the highest sensitivity, a high NPV and also an 
acceptable PPV, and can therefore be recommended. An increase in the sensitivity 
could be achieved by the combination of two drug interaction screening programs. 
Considering PV, possible improvements include the correct linking of drug names, a 
more precise linking of the references to the text in the monographs, an enlargement 
of the drug list and an edition in English. 
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Abstract 
Introduction 
The aim of this study was to assess potential drug-drug interactions (pDDIs) at 
hospital admission, during hospitalization and at discharge and to evaluate the 
number of pDDIs created during hospitalization due to changes in the medication. In 
addition, the clinical management of pDDIs by the physicians was investigated. 
Methods 
The medication of 851 patients was screened for pDDIs at hospital admission, during 
hospitalization and at discharge using the drug interaction screening program 
Pharmavista. Potential DDIs classified major and moderate were assessed 
separately. We focused in particular on four drug interaction groups to investigate the 
clinical management of pDDIs. 
Results 
At hospital discharge significantly more pDDIs per patient (1.6) were detected than at 
hospital admission (1.3) (p = 0.005). During hospitalization, the frequency of pDDIs 
was 2.5. When only major and moderate pDDIs per patient were considered, no 
significant difference between hospital admission and discharge was detected. The 
number of major or moderate pDDIs per drug pair administered was 4.5 at hospital 
admission, 1.6 during hospitalization and 2.3 at discharge. 47% of all major and 
moderate pDDIs at discharge were due to a medication change during 
hospitalization. Several deficiencies were detected regarding the management of 
clinically relevant pDDIs. 
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Conclusion 
Although the number of drugs increased from hospital admission to discharge by 
50%, the number of major and moderate pDDIs per patient did not. In fact, the 
number of pDDI per drug pair administered was reduced by 50%. 47% of all major 
and moderate pDDIs at discharge were created by medication changes during 
hospitalization. Prescribing drugs with a low risk for pDDIs as well as careful 
monitoring for adverse drug reactions are important measures to prevent harm 
associated with pDDIs. 
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Introduction 
According to a recently published study one percent of all hospital admissions were 
caused by drug-drug interactions (DDIs), corresponding to 16% of all patients 
admitted with adverse drug reactions (ADR) [1]. In a recent review, an incidence of 
up to 2.8% of hospital admissions were found to be caused by ADRs due to DDIs [2]. 
The clinical outcome of a potential (p)DDI is often unknown, and epidemiological data 
dealing with this problem are rare. However, it was pointed out by Hamilton et al. [3] 
that exposure to DDIs was associated with a significantly increased risk of 
hospitalization. 
The prevalence of pDDIs in the medication of ambulatory patients [4-6], of patients at 
hospital admission [7, 8], during hospitalization [9, 10], and at discharge [11-13] was 
assessed by numerous studies. One study assessed pDDIs for each patient at 
hospital admission, at discharge, and three months after discharge [14]. Changes in 
medication at the transition point from outpatient to inpatient care and back may 
increase the frequency of drug-related problems such as pDDIs [15, 16]. Drug 
modifications shortly before hospital discharge may be important in this context, 
because the monitoring of patients significantly declines after hospital discharge [17]. 
The aim of this study was to consecutively assess the frequency of pDDIs at hospital 
admission, during hospital stay on a medical ward and at hospital discharge. Further, 
we wanted to evaluate how many pDDIs were due to a change in prescriptions 
during hospitalization. Additionally, we attempted to analyze the clinical management 
of specific pDDIs by physicians. 
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Methods 
Study design, patients and data collection 
The study was conducted at the Cantonal Hospital of Baden, Switzerland. The 
hospital is a 400-bed teaching institution serving a population of approximately 
250’000 inhabitants. 
Between February and July 2004, patients admitted consecutively to three medical 
wards were included in the study. Information on drugs prescribed at hospital 
admission, during hospital stay and at discharge was retrieved from clinical records 
and the hospital discharge letters. Medication prescribed “as required” was included, 
regardless of whether it was administered or not. The medication for inpatients was 
recorded on a specific day once a week and once per patient. 
Demographic information (age and sex), length of hospital stay, main diagnosis 
(according to the international classification of diseases, 10th revision (ICD-10)) and 
the number of additional diagnoses were obtained from the clinical records. 
Classification of drug-drug interactions 
The medication at hospital admission, during hospital stay and at hospital discharge 
was screened for pDDIs using the drug interaction screening program Pharmavista 
[18]. This drug interaction screening program originates from the “ABDA-Datenbank” 
published by the “Bundesvereinigung Deutscher Apothekerverbände” (federal 
organization of the German pharmacist associations). The program was chosen as a 
result of our evaluation of frequently used drug interaction screening programs [19]. 
In this publication, we recommended Pharmavista as the program with the highest 
sensitivity for detecting pDDIs, for its high negative and positive predictive values. 
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For each interacting drug combination, Pharmavista provides information on the 
possible ADR, the clinical management and the mechanism of the DDI and provides 
literature references regarding the DDI. 
The program classifies severities of DDIs into five categories: majori, moderateii, 
minoriii, insignificantiv and unidentified sourcev. In this study, DDIs of the severities 
major, moderate and minor were included for analysis; additionally, major and 
moderate DDIs were analyzed separately. 
Analysis of four groups of drug-drug interactions 
We chose four well-known groups of DDIs to evaluate their prevalence and clinical 
management in more detail: drug-statin interactions, DDIs resulting in increased risk 
for hyperkalaemia, interactions between bisphosphonates and polyvalent cations and 
drug - nonsteroidal antiinflammatory drug (NSAID) interactions resulting in increased 
risk for gastrointestinal bleeding. 
                                                 
i Major interactions may be life-threatening, or intoxication or permanent damage may be induced. 
Normally, these drugs should not be administered together. 
ii Moderate interactions frequently cause therapeutic difficulties, but the combinations may be 
administered if the patient is carefully monitored (laboratory parameters, for example quick value, or 
clinical symptoms). 
iii Minor interactions may cause increased or reduced effects or interactions only concerning a certain 
subgroup (for example patients with renal or hepatic failure, slow acetylizers). 
iv Insignificant interactions cause mainly no or unimportant effects and no special action is required. 
v Within interactions classified as unidentified source no medical literature is available. Only isolated 
cases are cited or even postulated, and their clinical relevance is unclear. 
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Statistical analysis 
Descriptive data were expressed as means with corresponding 95% confidence 
intervals (CIs), as medians and ranges, or as proportions. The Student’s t-test was 
used for independent two-sample comparisons. A two-sided p-value less than 0.05 
was considered statistically significant. Data were analyzed with R for Windows 
version 2.2.0 (R Development Core Team (2005), R Foundation for Statistical 
Computing, Vienna, Austria). 
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Results 
Patient characteristics and dropouts 
A total of 851 patients were enrolled. The patient characteristics are displayed in 
Table I. The median age of the patients was 72 years. Slightly more than half of the 
patients were male (53%). Patients showed a median number of three coded 
diagnoses. However, due to the gain of economical importance of the coding, gaps 
were closed and the number of coded diagnoses increased to a median of four. 
Diseases of the circulatory system were most often specified as main diagnosis 
(27%). 
Upon analysis of the prescriptions at hospital admission, 131 (15%) patients were 
excluded (115 patients because of insufficient information about medication and  
16 patients because of incomplete medical history). Concerning the analysis of 
prescriptions at hospital discharge, 48 (5.6%) patients were excluded (43 patients 
died during hospitalization and five patients were excluded due to gaps in their 
medical history). 
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Table I: Characteristics of the 851 patients included in the study 
Characteristics  n = 851 
   
Mean 68.4 
95% Confidence interval 67.4 - 69.4 
Median 72 
Age - yr 
Range 18 - 99 
Male 454 (53.3) Sex - no. (%) 
Female 397 (46.7) 
Mean 12.0 
95% Confidence interval 11.3 - 12.6 
Median 9 
Length of hospital stay - days 
Range 1 - 106 
Mean 4.8 
95% Confidence interval 4.5 - 5.0 
Median 4 
Time between admission and collection 
of the drugs prescribed at the hospital 
staya - days 
Range 0 - 34 
Mean 3.3 
95% Confidence interval 3.2 - 3.4 
Median 3 
Coded number of diagnoses 
Range 1 - 9 
Diseases of the circulatory system 233 (27.4) 
Diseases of the digestive system 99 (11.6) 
Diseases of the respiratory system 88 (10.3) 
Main diagnoses (according to ICD-10) - 
no. (%) 
Neoplasms 88 (10.3) 
 Symptoms, signs and abnormal clinical 
and laboratory findings, not elsewhere 
classified 
82 (9.6) 
 Diseases of the musculoskeletal 
system and connective tissue 
50 (5.9) 
 Diseases of the nervous system 39 (4.6) 
 Factors influencing health status and 
contact with health services 
35 (4.1) 
 Others (< 3%) 137 (16.1) 
a. see Methods 
ICD-10 = international classification of diseases, 10th revision, n = number of patients, no. = number, 
yr = year 
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Prescribed drugs 
The median total number of drugs prescribed was four at hospital admission,  
11 during hospital stay and six at hospital discharge (Table II). During hospital stay, 
the median number of drugs without considering those prescribed “as required” was 
eight. The number of drugs prescribed at hospital discharge was significantly higher 
than at hospital admission (p < 0.001). 
Table II: Number of drugs and number of drug pairs per patient at hospital admission, during 
hospitalization and at hospital discharge 
  At hospital 
admission 
(n = 720) 
During 
hospitalization 
(n = 851) 
At hospital 
discharge 
(n = 803) 
     
Mean 4.1 7.8 6.2 
95% CI 3.9 - 4.4 7.5 - 8.1 6.0 - 6.4 
Median 4 8 6 
Number of drugs, excluding drugs 
prescribed “as required” 
Range 0 - 17 0 - 27 0 - 19 
Mean 0.2 3.7 0.4 
95% CI 0.2 - 0.3 3.6 - 3.9 0.4 - 0.5 
Median 0 4 0 
Number of drugs, prescribed “as 
required” 
Range 0 - 4 0 - 10 0 - 6 
Mean 4.3 11.6 6.6 
95% CI 4.1 - 4.6 11.2 - 11.9 6.4 - 6.9 
Median 4 11 6 
Total number of drugs 
Range 0 - 17 2 - 34 0 - 21 
Mean 13.0 71.5 26.0 
95% CI 11.6 - 14.5 67.5 - 75.4 24.1 - 27.9 
Median 6 55 15 
Number of drug pairs 
Range 0 - 136 1 - 561 0 - 210 
95% CI = 95% confidence interval, n = number of patients 
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Figure I displays the proportion of patients with at least one prescription belonging to 
the specified drug class (according to the anatomical therapeutical chemical (ATC) 
classification). Drugs affecting the central nervous system (e.g. oxazepam, 
lorazepam, valerian) were prescribed for 99% of the inpatients, but the majority of 
these drugs (68%) was prescribed “as required”. At hospital admission, 44% of all 
patients were prescribed a drug affecting the central nervous system and 61% of the 
patients at hospital discharge. The other three most prevalent anatomical groups 
were drugs affecting the alimentary tract and metabolism (admission 46%, inpatients 
79%, discharge 72%), drugs affecting the blood and blood forming organs (admission 
45%, inpatients 80%, discharge 60%) and drugs affecting the cardiovascular system 
(admission 61%, inpatients 77%, discharge 71%). These four groups represented 
82% of all drugs at hospital admission, 84% during hospital stay and 85% at hospital 
discharge. 
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Figure I: Proportion of patients (> 5%) with prescriptions belonging to the drug classes according to 
the anatomical therapeutical chemical (ATC) classification at hospital admission (n = 720), inpatients 
(n = 851) and hospital discharge (n = 803) 
n = number of patients; anatomical main groups: A = alimentary tract and metabolism, B = blood and 
blood forming organs, C = cardiovascular system, D = genito urinary system and sex hormones,  
H = systemic hormonal preparations, exclusive sex hormones and insulins, J = antiinfectives for 
systemic use, L = antineoplastic and immunomodulating agent, M = musculo-skeletal system,  
N = nervous system, R = respiratory system 
 
During hospital stay, all drug classes – except drugs affecting the genito-urinary 
system and drugs affecting the musculo-skeletal system – had the highest 
prescription frequency. Antiinfectives for systemic use as well as drugs affecting the 
respiratory system were administered to four times more patients during 
hospitalization as compared to patients at hospital admission or discharge. 
Drug-drug interactions in general 
The prevalence of pDDIs at hospital admission, during hospital stay as well as at 
hospital discharge is shown in detail in Table III. At hospital entry 47% of the patients 
had at least one pDDI. This figure increased during hospitalization to 73% and 
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dropped at discharge to 59%. Considering pDDI classified as major or moderate 
only, the frequencies were 30% at hospital entry, 56% during hospitalization and  
31% at discharge. When expressed per patient, the corresponding figures for major 
and moderate pDDIs were 0.59 at entry, 1.11 during hospitalization and 0.60 at 
discharge. Regarding major and moderate pDDIs expressed per patient, the value for 
inpatients was significantly higher than at admission or at discharge, whereas there 
was no difference between entry and discharge. 
Table III: Prevalence of potential drug-drug interactions (pDDIs) in the medication at hospital 
admission, during hospitalization and at hospital discharge 
  At hospital 
admission 
(n = 720) 
During 
hospitalization 
(n = 851) 
At hospital 
discharge 
(n = 803) 
     
no. (%) 4 (0.6) 26 (3.1) 5 (0.6) Number of patients with ≥ one major 
pDDI 95% CI (%) 0.0 - 1.2 1.8 - 4.0 0.0 - 1.2 
no. (%) 215 (29.9) 478 (56.2) 248 (30.9) Number of patients with ≥ one major or 
moderate pDDI 95% CI (%) 26.5 - 33.3 52.8 - 59.6 27.6 - 34.2 
no. (%) 339 (47.1) 625 (73.4) 473 (58.9) Number of patients with ≥ one major, 
moderate or minor pDDI 95% CI (%) 43.4 - 50.8 70.4 - 76.4 55.4 - 62.4 
Mean 0.01 0.03 0.01 
95% CI 0.00 - 0.01 0.02 - 0.05 0.00 - 0.01 
Median 0 0 0 
Number of major pDDIs per patient 
Range 0 - 1 0 - 2 0 - 1 
Mean 0.59 1.11 0.60 
95% CI 0.50 - 0.68 1.00 - 1.21 0.51 - 0.68 
Median 0 1 0 
Number of major or moderate pDDIs 
per patient 
Range 0 - 12 0 - 11 0 - 9 
Mean 1.3 2.5 1.6 
95% CI 1.1 - 1.4 2.3 - 2.7 1.4 - 1.7 
Median 0 1 1 
Number of major, moderate or minor 
pDDIs per patient 
Range 0 - 16 0 - 19 0 - 18 
95% CI = 95% confidence interval, n = number of patients, no. = number 
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The prevalence of major or moderate pDDIs in proportion to the number of drugs 
(Table IV) declines from 13.7% (0.59 of 4.3) at hospital admission to 9.6% (1.11 of 
11.6) during hospitalization and to 9.1% (0.60 of 6.6) at discharge. The ratio between 
the number of major and moderate pDDIs and the number of drug pairs was lowest 
during hospitalization (1.6%, 1.11 of 71.5) and highest at hospital admission (4.5%, 
0.59 of 13.0). 
Table IV: Prevalence of major or moderate potential drug-drug interactions (pDDIs) in proportion to the 
number of drugs and to the number of drug pairs at hospital admission, during hospitalization and at 
hospital discharge 
  At hospital 
admission 
(n = 720) 
During 
hospitalization 
(n = 851) 
At hospital 
discharge 
(n = 803) 
     
Total number of drugs Mean 4.3 11.6 6.6 
Number of major or moderate pDDIs per 
patient 
Mean 0.59 1.11 0.60 
Number of drug pairs Mean 13.0 71.5 26.0 
Mean number of major or moderate pDDI / 
mean number of drugs 
Ratio (%) 13.7 9.6 9.1 
Mean number of major or moderate pDDI / 
mean number of drug pairs 
Ratio (%) 4.5 1.6 2.3 
n = number of patients 
 
For 697 patients, all prescriptions at admission, during hospital stay and at discharge 
could be analyzed. Focusing on major and moderate pDDIs, 406 were present at 
hospital admission, whereof 103 (25%) were eliminated during the first days of 
hospitalization. During hospitalization, an additional 450 pDDIs were generated due 
to new medications, resulting in a total of 753 pDDIs. Almost half of these pDDIs 
(365, 49%) were eliminated at hospital discharge, when only eight new pDDIs were 
detected compared to the inpatient medication. Out of 396 DDIs at hospital 
discharge, 185 (47%) were due to a medication change during the hospital stay. 
Regarding major pDDIs only, out of three pDDIs at hospital admission two were 
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eliminated during hospitalization. During hospital stay, 21 major pDDIs were created, 
whereof 18 were eliminated at hospital discharge. 
Table V lists all major pDDIs and the most prevalent moderate pDDIs, which account 
for 62% of all major and moderate pDDIs at hospital admission, for 67% at hospital 
stay and for 61% at hospital discharge. 
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Table V: Major and moderate potential drug-drug interactions (pDDIs) at hospital admission, during 
hospitalization and at hospital discharge. All major pDDIs are listed, whereas for the moderate pDDIs 
only those are listed with a frequency of ≥ 3% among the patients. 
   Patients with pDDIs - no. (%) 
Drug combination Potential adverse 
effect 
Severity At hospital 
admission 
(n = 720) 
During 
hospitalization 
(n = 851) 
At hospital 
discharge 
(n = 803) 
      
Potassium + potassium-
sparing diuretic 
Hyperkalaemia Major 1 (0.1) 12 (1.4) 3 (0.4) 
Beta-sympathomimetic 
agent + non-cardio-
selective beta-blocker 
Decreased effect of 
beta-sympathomimetic 
agent 
Major 2 (0.3) 6 (0.7) 0 (0.0) 
Macrolide antibiotic + 
statin 
Increased risk of 
myopathy including 
rhabdomyolysis 
Major 0 (0.0) 4 (0.5) 1 (0.1) 
Heparinoid + salicylate 
(high-dose) 
Increased risk of 
bleeding 
Major 0 (0.0) 4 (0.5) 0 (0.0) 
MAO inhibitor + opioid Increased risk of 
adverse reactions 
affecting the central 
nervous system 
Major 1 (0.1) 1 (0.1) 1 (0.1) 
Heparinoids + salicylate 
(low-dose) 
Increased risk of 
bleeding 
Moderate 6 (0.8) 193 (22.7) 31 (3.9) 
Diuretic + glucocorticoid Risk for hypokalaemia Moderate 65 (9.0) 106 (12.5) 67 (8.3) 
Diuretic + NSAID Decreased diuretic and 
antihypertensive effect 
Moderate 40 (5.6) 38 (4.5) 28 (3.5) 
ACE inhibitor + NSAID Decreased antihyper-
tensive effect 
Moderate 22 (3.1) 36 (4.2) 20 (2.5) 
Glucocorticoid + NSAID Increased risk of 
bleeding 
Moderate 24 (3.3) 35 (4.1) 22 (2.7) 
Beta-blocker + insulin Increased risk for 
hypoglycaemia 
Moderate 12 (1.7) 35 (4.1) 20 (2.5) 
ACE inhibitor + 
potassium salt 
Risk for hyperkalaemia Moderate 5 (0.7) 34 (4.0) 7 (0.9) 
ACE inhibitor + 
potassium-sparing 
diuretic 
Risk for hyperkalaemia Moderate 22 (3.1) 30 (3.5) 25 (3.1) 
Antidiabetes agent + 
glucocorticoid 
Impaired blood glucose 
control 
Moderate 11 (1.5) 23 (2.7) 19 (2.4) 
Beta-blocker + NSAID Decreased antihyper-
tensive effect 
Moderate 21 (2.9) 22 (2.6) 16 (2.0) 
Bisphosphonate + 
polyvalent cation 
Decreased bioavaila-
bility of bisphosphonate 
Moderate 18 (2.5) 19 (2.2) 14 (1.7) 
Oral anticoagulant + 
thyroid hormone 
Decreased anticoagu-
lant effectiveness 
Moderate 10 (1.4) 10 (1.2) 15 (1.9) 
ACE = angiotensin-converting enzyme, MAO = monoamine oxidase, n = number of patients,  
no. = number, NSAID = nonsteroidal antiinflammatory drug 
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More than 70% of all major and moderate pDDIs are caused by a pharmacodynamic 
mechanism (hospital admission 71%, inpatients 76%, hospital discharge 72%), 
whereas pharmacokinetic mechanisms were observed in 27% of pDDIs at hospital 
admission, in 22% of pDDIs during hospital stay and in 26% of pDDIs at hospital 
discharge. The remaining pDDIs had a combined or an unknown mechanism. 
Concerning the pharmacokinetic pDDIs, approximately half of them could be 
explained by inhibition of induction of metabolic enzymes, in particular the 
cytochrome P450 (CYP) system (15% of pDDIs at hospital admission and at hospital 
discharge, 12% at hospitalization). 
Drug - statin interactions at hospital discharge 
At hospital discharge, nine drug - statin interactions resulting in an increased risk for 
myopathy and rhabdomyolysis were observed. Six pDDIs were due to atorvastatin,  
two to simvastatin and one to pravastatin. As CYP3A4-inhibiting drugs amiodarone 
(4), verapamil (2) and clarithromycin (1) were found. Within two statin - cyclosporine 
interactions (atorvastatin and pravastatin) inhibition of the organic anion transporting 
polypeptide (OATP-2) mediated hepatic uptake of statins by cyclosporine, leading to 
increased statin plasma concentrations, is supposed [20, 21]. Five drug - statin 
interactions resulted from new prescriptions (atorvastatin in a patient treated with 
cyclosporine, atorvastatin in two patients treated with amiodarone, simvastatin in a 
patient treated with verapamil, and clarithromycin in a patient treated with 
atorvastatin). 
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Potential drug-drug interactions resulting in increased risk for hyperkalaemia 
At hospital discharge, 37 pDDIs (in 36 patients) resulting in an increased risk for 
hyperkalaemia were detected, whereof 25 (68%) were attributed to the combination 
angiotensin-converting enzyme (ACE) inhibitors and potassium-sparing diuretics.  
Three (8%) of these pDDIs (potassium salts and potassium-sparing diuretics) were 
classified as major. A potassium-wasting diuretic (loop diuretic and/or thiazide) was 
included in the medication regimen of 31 (84%) of these patients. The mean serum 
potassium level at discharge was 4.0 mmol/L (95% CI 3.8 - 4.1 mmol/L, range  
2.9 - 5.2 mmol/L). The mean estimated creatinine clearance was 66 mL/min (95% CI 
53 - 79 mL/min, range 16 - 161 mL/min). Two patients with the combination of an 
ACE inhibitor with spironolactone showed potassium levels above the normal range 
(3.5 - 4.8 mmol/L). One of these patients (serum potassium level 5.2 mmol/L) had a 
severely impaired renal function (estimated creatinine clearance 16 mL/min), which 
represents an additional risk factor for hyperkalaemia. The other patient (serum 
potassium level 4.9 mmol/L) had only a slight impairment of renal function (estimated 
creatinine clearance 64 mL/min) and was treated with a loop diuretic. 
Interactions between bisphosphonates and polyvalent cations at hospital discharge 
67% of the patients treated with a bisphosphonate (14 of 21 patients, 13 alendronic 
acid, 1 clodronic acid) were discharged with a polyvalent cation (13 calcium 
carbonate, 1 magnesium aspartate). According to the hospital discharge letters, in  
12 patients the polyvalent cation was to be administered with an insufficient time 
interval to the bisphosphonate. Only two patients were advised to take the calcium at 
lunchtime. 
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Drug - nonsteroidal antiinflammatory drug interactions resulting in increased risk for 
gastrointestinal bleeding 
Drug - NSAID interactions resulting in increased risk for gastrointestinal bleeding 
(NSAIDs combined with oral anticoagulants, glucocorticoids or thrombocyte 
aggregation inhibitors) rose from 5.3% (38 of 720 patients) at hospital admission to 
8.3% (67 of 803 patients) at hospital discharge. At hospital discharge, 5.5% (44) of all 
patients received the combination of a NSAID and a thrombocyte aggregation 
inhibitor (at admission 1.4%), 2.7% (22) were treated with the combination NSAID 
and glucocorticoid (at admission 3.3%) and one patient (0.1%) was prescribed an 
oral anticoagulant and a NSAID (at admission 0.6%). 42 of the 44 thrombocyte 
aggregation inhibitor - NSAID interactions were due to the combination with 
clopidogrel and/or low-dose aspirin. Approximately half of these patients (20) were 
treated with an antacid drug such as a proton pump inhibitor (PPI) in addition. One 
patient was treated with the combination low-dose aspirin and ibuprofen, which can 
blunt the effect of aspirin when ingested together [22]. 
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Discussion 
Our study shows that the number of drugs prescribed per patient increased 
significantly from hospital admission to discharge, whereas the number of major and 
moderate pDDIs per patient was not higher at discharge compared to admission. 
During hospitalization, the number of prescribed drugs as well as the number of 
major and moderate pDDIs per patient was significantly higher than at hospital 
admission and discharge. In relation to the number of drugs as well as to the number 
of drug pairs, the prevalence of pDDIs even decreased from hospital entry to 
discharge. Approximately 50% of all moderate and major pDDI at discharge were 
due to changes in the medication during hospitalization. 
The figures found in our study compare well with similar reports in the literature. 
Egger et al. retrospectively screened the medication for pDDIs of 500 medical 
patients only at hospital admission and discharge, but not at hospital stay [12]. The 
patient characteristics as well as the drugs used were quite similar to those in our 
study. The results showed that – although another drug interaction screening 
program (Drug-Reax [23]) was used – the prevalence of patients with at least one 
pDDI at hospital admission (48%) and at hospital discharge (60%) was comparable 
to our results. Straubhaar et al. studied the prevalence of pDDIs in patients with heart 
failure. They found that 68% of patients at hospital admission and 89% of patients at 
hospital discharge had at least one pDDI [13]. These data are not directly 
comparable with our study because of different patient characteristics and drug 
prescriptions. Köhler et al. used the same data base (“ABDA Datenbank”) as 
Pharmavista for screening prescriptions of patients at hospital entry and discharge 
[14]. Unfortunately, the classification of severities by Pharmavista changed between 
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1996 and 2004, and therefore the results are not directly comparable. The mean 
number of all pDDIs per patient at hospital admission and discharge were 1.5  
(vs 1.4 in our study) and 1.7 (vs 1.8), respectively. The proportion of patients free of 
pDDIs at hospital admission was 44% (vs 53% in our study), and 40% at discharge 
(vs 41%). Concerning major pDDIs, Köhler et al. found a slight increase in the 
number of pDDIs per patient between hospital admission and hospital discharge 
(0.02 at admission, 0.04 at discharge), which is in contrast with the results of our 
study. 
Potential DDIs with a higher frequency during hospitalization were potassium 
supplements in patients treated with potassium sparing diuretics or ACE inhibitors or 
angiotensin receptor blockers, macrolide antibiotics in patients treated with statins, 
non-cardioselective beta-blockers in patients treated with β2-sympathomimetics, 
beta-blockers in diabetics and the combination of heparinoids in patients treated with 
cardiovascular or analgesic doses of aspirin. 
Regarding the combination of potassium supplements with potassium sparing 
diuretics, ACE inhibitors or angiotensin receptor blockers, this combination appears 
to be acceptable in the hospital, since serum potassium levels and renal function can 
be monitored closely. However, when patients are discharged, the combination 
should be discontinued in order to avoid potentially life-threatening hyperkalaemia. In 
our study, 4.5% (36 patients) of the patients at hospital discharge were exposed to 
pDDIs that could have resulted in hyperkalaemia. All of these patients had the 
combination spironolactone and ACE inhibitor, which is common in patients with 
heart failure [6, 13]. None of the patients was discharged with potassium 
supplements in combination with spironolactone, ACE inhibitors or angiotensin 
receptor blockers. 
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The combination of macrolides (erythromycin, roxithromycin, clarithromycin) with 
statins metabolized by CYP3A4 (atorvastatin, lovastatin, simvastatin) should be 
avoided, since it increases the risk for myopathies [24, 25]. The risk for rhabdo-
myolysis in patients treated with a statin without pDDI has been estimated to be in 
the range of 1:10’000 patient years [26]. This risk increases approximately by a factor 
of ten (to 1:1’000 patient years), when a CYP3A4 inhibitor is co-administered [6]. In 
the case of macrolide antibiotics, which are usually used for one to two weeks only, 
the statin should be stopped during treatment. In our patients, the prevalence of drug 
- statin interactions in statin-treated patients declined from 8.4% (10 pDDIs in  
119 statin-treated patients) at hospital admission to 5.6% (12 pDDIs in 213 statin-
treated patients) during hospital stay and 4.0% (9 pDDIs in 226 statin-treated 
patients) at hospital discharge. Rätz et al. found a prevalence of 6.9% drug - statin 
interactions in ambulatory patients with statin treatment [6]. Out of nine drug - statin 
interactions at hospital discharge, seven could have been avoided by choosing a 
statin which is not metabolized by CYP3A4 [27]. 
The concomitant use of non-cardioselective beta-blockers with β2-symapthomimetics 
should generally be avoided. Non-cardioselective beta-blockers not only decrease 
the efficacy of β2-sympathomimetics, but are also mostly contraindicated in the 
patients where β2-sympathomimetics are indicated. If beta-blockers are to be used in 
such patients, cardioselective beta-blockers should be preferred but only under close 
monitoring of pulmonary function [28]. 
The use of beta-blockers in patients with diabetes mellitus is a matter of debate. Due 
to the possibility that the symptoms associated with hypoglycaemia are mitigated and 
glycogenolysis is impaired, the risk for hypoglycaemia may be increased. While this 
is the case for non-cardioselective beta-blockers [29], cardioselective beta-blockers 
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can be considered to be safe in diabetics [30, 31]. We therefore advise to avoid non-
cardioselective beta-blockers in diabetics and to prefer cardioselective beta-blockers, 
but only in patients with a clear indication. Furthermore, the patients should know that 
tachycardia may not develop despite hypoglycaemia, but that sweating may be 
increased [30]. 
The combination of thrombocyte aggregation inhibitors with heparins is associated 
with a higher risk of bleeding than either treatment alone, but this risk is outweighed 
by the improved antithrombotic efficacy of this combination in certain groups of 
patients such as patients with an acute coronary syndrome [32, 33]. On the other 
hand, analgesic doses of aspirin or other NSAIDs should most probably not be 
combined with heparins, due to the local effects of NSAIDs in the gastrointestinal 
tract, which may bleed. While the combination of NSAIDs with oral anticoagulation 
has clearly been shown to be associated with a very high risk for bleeding and should 
therefore be avoided [34], such data do – to the best of our knowledge – not exist for 
the combination with heparin. 
Limitations 
Concerning the medication at hospital admission, possibly incomplete medical record 
documentation has to be considered. Recent studies showed discrepancies in 40 to 
50% of patients between medical record and patient-reported use of drugs [35-37]. 
For non-prescription NSAIDs, disagreement was found in 74% of patients’ 
medication [37]. A systematic review found that up to 61% of cases had at least one 
omission error in prescription medication histories [38]. 
Another limitation concerns drugs prescribed “as required”, since we do not know if 
patients actually ingested this medication. However, DDIs might have occurred if they 
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had been administered to the patient. Therefore, physicians should be careful 
regarding pDDIs when prescribing drugs “as required”. 
Further, clinically manifest DDIs were not a concern of this study and therefore we 
use the expression potential DDI. Data about negative clinical outcomes caused by 
DDIs are rare, but some retrospective studies have been published. Ray et al. 
showed that the rate of sudden death from cardiac causes was five times as high 
among patients who concurrently used CYP3A inhibitors and erythromycin [39]. 
Juurlink et al. calculated odds ratios of 6.6 for hypoglycaemia in patients treated with 
glyburide in combination with co-trimoxazole, 11.7 for digoxin toxicity in patients 
treated with clarithromycin and 20.3 for hyperkalaemia in patients with ACE inhibitors 
combined with potassium-sparing diuretics [40]. 
Another limitation concerns the drug interaction screening program. Although our 
evaluation showed that Pharmavista provides high sensitivity and sophisticated 
information about DDIs (mechanism and clinical management) [19], some 
improvement is desirable. For example, pulmonary inhalation of glucocorticoids is not 
distinguished from systemic use of glucocorticoids, and thus the combination of 
inhaled glucocorticoid and low-dose aspirin is designated as a moderate pDDI. The 
same problem is present with diuretic drugs and pulmonary glucocorticoid treatment. 
No information about negative outcomes concerning these combinations with locally 
administered glucocorticoids was found in Stockley’s drug interactions [41], a 
comprehensive monograph of DDIs. Furthermore, no differentiation is made between 
cardioselective and non-cardioselective beta-blocking agents concerning use in 
diabetics. 
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Conclusion 
Although the number of drugs increased from hospital admission to discharge by 
50%, the number of major and moderate pDDIs per patient did not increase. Despite 
of these results, it is important to realize that 47% of all major and moderate pDDIs at 
discharge were created by medication changes during hospitalization. Prescribing 
drugs with a low risk for pDDIs as well as careful monitoring for ADRs are important 
measures to prevent harm associated with pDDIs. 
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Abstract 
Introduction 
The aim of this study was to improve the clinical management of potential drug-drug 
interactions (pDDIs) by pharmacist interventions during hospitalization and at hospital 
discharge. 
Methods 
During the first study period inpatients in three medical wards and during the second 
study period patients discharged from three medical wards were screened for major 
and moderate pDDIs using the drug interaction screening program Pharmavista. 
After assessment for clinical relevance of the detected pDDIs by a pharmacist, 
written recommendations and information about the pDDIs were sent to the 
physicians. Feedback from the physicians and their subsequent implementations 
were analyzed. 
Results 
During the first study period, 502 inpatients were exposed to 567 major or moderate 
pDDIs. 419 (74%) of these pDDIs were judged clinically relevant by the pharmacist. 
349 recommendations including pDDI information, and 70 simply information leaflets 
were handed out to the physicians. 80% (278 of 349) of the recommendations were 
accepted. At hospital discharge, in 78% (47 of 60 reviewed instances, which were 
accepted) the drug changes due to the recommendations were implemented. 
During the second study period, 792 patients at hospital discharge were exposed to 
392 major and moderate pDDIs. 258 (66%) pDDIs were assessed as clinically 
relevant by the pharmacist. 247 recommendations including pDDI information, and 
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11 simply information leaflets were sent to the physicians. 73% (180 of 247) of the 
recommendations were accepted. One year after hospital discharge, 11 of 13 drug 
changes due to recommendations were still existent. 
Overall, in 50% and 46%, respectively, of all major and moderate pDDIs detected by 
Pharmavista, clinical management was adapted accordingly. 
Conclusion 
The management of clinically relevant pDDIs can be improved by physicians’ advice 
of clinical pharmacists. Changes in medication due to pDDIs were found to persist up 
to one year after hospital discharge. 
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Introduction 
Medication errors, adverse drug events (ADEs) and adverse drug reactions (ADRs) 
are common and clinically important problems. ADEs and ADRs are associated with 
considerable morbidity and mortality [1-12]. According to a recently published study 
one percent of all hospital admissions was caused by drug-drug interactions (DDIs), 
corresponding to 16% of all patients admitted with ADRs [9]. A review of nine ADR 
studies found an incidence up to 2.8% of DDIs as a cause of hospital admissions 
[13]. In recent years major progress in our understanding of DDIs has been made, 
particularly in the molecular mechanism by which drugs interact. But our ability to 
appropriately apply this information to specific patients has lagged behind and 
patients continue to suffer from adverse DDIs. 
Changes in medication at the transition point from outpatient to inpatient care and 
vice versa may increase the frequency of drug-related problems such as potential 
(p)DDIs [10, 14-16]. In our study on the prevalence of pDDIs during hospital stay, 
47% of all pDDIs at discharge were created by medication changes during 
hospitalization. Furthermore, several deficiencies were detected regarding the clinical 
management of pDDIs. 
The aim of this study was to improve the clinical management of pDDIs by 
pharmacist interventions during hospitalization and at hospital discharge. 
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Methods 
Patients and data collection 
The intervention study was conducted at the Cantonal Hospital of Baden, 
Switzerland. The hospital is a 400-bed teaching institution serving a population of 
approximately 250’000 inhabitants. The Clinic of Medicine is not (yet) equipped with 
a computerized physician order entry (CPOE) and therefore no automatic DDI order 
check was available. 
Between February and May 2005, patients admitted to three medical wards were 
included in the first part of the study (intervention period during hospitalization). 
Information on drugs prescribed during hospitalization was retrieved from clinical 
records and was collected on a fixed day once a week and once per patient. 
Between June and October 2005, patients discharged from three medical wards 
were included in the second part of the study (intervention period at hospital 
discharge). Information on drugs prescribed at discharge was obtained from the 
hospital discharge letters on the day of discharge. 
Demographic information (age and sex), length of hospital stay, main diagnosis 
(according to the international classification of diseases, 10th revision (ICD-10)) and 
the number of additional diagnoses were obtained from the clinical records. 
Classification of the potential drug-drug interactions 
Medication was screened for pDDIs using the drug interaction screening program 
Pharmavista [17]. This drug interaction screening program originates from the 
“ABDA-Datenbank” published by the “Bundesvereinigung Deutscher Apotheker-
verbände” (federal organization of the German pharmacist associations). The 
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program was chosen as a result of our evaluation of nine drug interaction screening 
programs [18]. In this publication, we recommended Pharmavista as the program 
with the highest sensitivity for detecting pDDIs, despite the limitation that it is written 
in German. The program classifies severities of DDIs into five categories: majori, 
moderateii, minoriii, insignificantiv and unidentified sourcev. 
Pharmacist’s intervention 
After the screening, pDDIs classified as major and moderate were assessed by a 
pharmacist, and for clinically relevant pDDIs recommendations in written form were 
prepared for the physicians. In addition to these recommendations, information 
leaflets according to Pharmavista on the possible ADR, the clinical management, the 
mechanism and literature references regarding the DDI were sent to the physicians. 
They were asked to give written feedback on the acceptance or rejection of the 
recommendation. In addition, within the second part of the study, physicians were 
asked to assess the clinical relevance of the pDDI themselves. 
                                                 
i Major interactions may be life-threatening, or intoxication or permanent damage may be induced. 
Normally, these drugs should not be administered together. 
ii Moderate interactions frequently cause therapeutic difficulties, but the combinations may be 
administered if the patient is carefully monitored (laboratory parameters, for example quick value, or 
clinical symptoms). 
iii Minor interactions may cause increased or reduced effects or interactions only concerning a certain 
subgroup (for example patients with renal or hepatic failure, slow acetylizers). 
iv Insignificant interactions cause mainly no or unimportant effects and no special action is required. 
v Within interactions classified as unidentified source no medical literature is available. Only isolated 
cases are cited or even postulated, and their clinical relevance is unclear. 
Drug-Drug Interactions in the Hospital  Intervention Study 
Priska Vonbach Inauguraldissertation, University of Basel Page 83 
Implementation during hospitalization was verified according to the medication 
prescribed at hospital discharge, which was checked for changes according to the 
recommendations. Concerning the interventions at hospital discharge, general 
practitioners were asked for details about current medication to prove the efficacy of 
drug changes due to the recommendation one year after the intervention. 
Statistical analysis 
Descriptive data were expressed as means with corresponding 95% confidence 
intervals (CIs), as medians and ranges, or as proportions. Data were analyzed with  
R for Windows version 2.2.0 (R Development Core Team (2005), R Foundation for 
Statistical Computing, Vienna, Austria). 
Intervention Study  Drug-Drug Interactions in the Hospital 
Page 84 Inauguraldissertation, University of Basel Priska Vonbach 
Results 
Dropouts and patient characteristics 
Between February and May 2005 (intervention during hospitalization), 539 patients 
were enrolled. Of these, 37 (7%) patients were excluded (31 patients died during 
hospitalization and six patients were excluded due to gaps in their medical history). 
The median time between hospital admission and the registration of the drugs 
prescribed during hospital stay was four days (mean 5.1 days, 95% CI 4.7 - 5.6 
days). 
Between June and October 2005 (intervention at hospital discharge), data 
concerning 826 patients were recorded at hospital discharge. 
The characteristics of the patients included in the study are displayed in Table I. 
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Table I: Characteristics of the patients included in the study 
Characteristics  Intervention during 
hospitalization 
(n = 502) 
Intervention at 
hospital discharge 
(n = 792) 
    
Mean 68.4 66.5 
95% CI 67.2 - 69.7 65.3 - 67.6 
Median 71 69 
Age - yr 
Range 17 - 96 17 - 99 
Male 231 (46) 404 (51) Sex - no. (%) 
Female 271 (54) 388 (49) 
Mean 13.0 9.3 
95% CI 12.1 - 13.9 8.6 - 9.9 
Median 10 7 
Length of hospital stay - 
days 
Range 1 - 91 1 - 72 
Mean 4.3 4.5 
95% CI 4.1 - 4.5 4.3 - 4.6 
Median 4 4 
Number of diagnoses 
Range 1 - 16 1 - 15 
Diseases of the circulatory 
system 
137 (27.3) 221 (27.9) 
Diseases of the respiratory 
system 
78 (15.5) 54 (6.8) 
Diseases of the digestive system 52 (10.4) 109 (13.8) 
Neoplasms 42 (8.4) 61 (7.7) 
Symptoms, signs and abnormal 
clinical and laboratory findings, 
not elsewhere classified 
36 (7.2) 22 (2.8) 
Factors influencing health status 
and contact with health services 
14 (2.8) 45 (5.7) 
Diseases of the nervous system 25 (5.0) 44 (5.6) 
Diseases of the musculo-skeletal 
system and connective tissue 
20 (4.0) 42 (5.3) 
Main diagnoses 
(according to ICD-10) - 
no. (%) 
Others (< 5%) 98 (19.5) 194 (24.5) 
95% CI = 95% confidence interval, ICD-10 = international classification of diseases, 10th revision,  
n = number of patients, no. = number, yr = year 
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Prescribed drugs and prevalence of major and moderate potential drug-drug 
interactions 
The number of prescribed drugs (and drug pairs) per patient as well as the 
prevalence of major and moderate pDDIs are presented in Table II. During the 
intervention period during hospitalization, less patients (n = 502) were recorded than 
during the intervention period at hospital discharge (n = 792). Due to a higher median 
value of the drugs prescribed to inpatients than at discharge (11 vs 6) the total 
number of major and moderate pDDIs was higher during hospitalization (567 pDDIs) 
than at hospital discharge (392 pDDIs). The prevalence of major and moderate 
pDDIs in proportion to the number of drugs was 9.8% (1.13 of 11.5) during 
hospitalization and 8.0% (0.49 of 6.1) at discharge, respectively. 
Table II: Number of drugs and drug pairs per patient and the prevalence of major and moderate 
potential drug-drug interactions (pDDIs) 
  Intervention during 
hospitalization 
(n = 502) 
Intervention at 
hospital discharge 
(n = 792) 
    
Mean (95% CI) 7.8 (7.5 - 8.1) 5.7 (5.5 - 5.9) Number of drugs, excluding drugs 
prescribed “as required” Median (Range) 7 (0 - 21) 5 (0 - 18) 
Mean (95% CI) 3.7 (3.6 - 3.8) 0.4 (0.3 - 0.4) Number of drugs, prescribed “as 
required” Median (Range) 3 (0 - 12) 0 (0 - 5) 
Mean (95% CI) 11.5 (11.1 - 11.9) 6.1 (5.9 - 6.3) Total number of drugs 
Median (Range) 11 (1 - 26) 6 (0 - 18) 
Mean (95% CI) 70.1 (65.3 - 74.9) 20.8 (19.3 - 22.4) Number of drug pairs 
Median (Range) 55 (0 - 325) 15 (0 - 153) 
no. (%) 22 (4.4) 6 (0.8) Number of patients with ≥ one 
major pDDI 95% CI (%) 2.6 - 6.2 0.15 - 1.36 
no. (%) 284 (56.6) 243 (30.7) Number of patients with ≥ one 
major or moderate pDDI 95% CI (%) 52.2 - 61.0 27.5 - 33.9 
Mean (95% CI) 0.05 (0.03 - 0.08) 0.01 (0.00 - 0.01) Number of major pDDIs per patient 
Median (Range) 0 (0 - 3) 0 (0 - 1) 
Mean (95% CI) 1.13 (0.98 - 1.27) 0.49 (0.43 - 0.56) Number of major or moderate 
pDDIs per patient Median (Range) 1 (0 - 13) 0 (0 - 7) 
95% CI = 95% confidence interval, n = number of patients, no. = number
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Pharmacist’s intervention 
As a result of the pharmacist’s assessment, 419 pDDIs were judged as clinically 
relevant (74% of 567 major and moderate pDDIs) during the intervention period for 
inpatients. 349 recommendations (including information about the DDI) and in  
70 cases simply Pharmavista general information leaflets were handed out to the 
physicians. 
Regarding the intervention period at hospital discharge, 258 pDDIs were assessed 
as clinically relevant (66% of 392 major and moderate pDDIs), and therefore 247 
recommendations (including information about the DDI) and in 11 cases simply 
Pharmavista information leaflets were provided to the physicians. 
Table III shows a summary of the recommendations. 47 (11%) recommendations 
during hospitalization and 29 (11%) recommendations at hospital discharge required 
a drug withdrawal, a replacement or a prescription of another drug. During the 
hospitalization intervention period, 130 recommendations were provided in addition 
to further advice to the general practitioner (111) and/or the patient (25) about the 
DDI and the possible ADRs. At hospital discharge, physicians were asked to transfer 
each recommendation to the general practitioners, and 17 additional advices about 
possible ADRs due to the DDIs were given to the patients. 
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Table III: Type of pharmaceutical recommendation concerning intervention to avoid major and 
moderate potential drug-drug interactions (pDDIs) 
Pharmaceutical recommendation Intervention during 
hospitalization 
(total number of 
interventions: 419) 
Intervention at 
hospital discharge 
(total number of 
interventions: 258) 
   
Withdrawal of a drug - no. (%) 5 (1.2) 5 (1.9) 
Withdrawal of a drug prescribed “as required” - no. (%) 13 (3.1) 0 (0.0) 
Replacement of a drug by another drug - no. (%) 30 (7.2) 24 (9.3) 
Replacement of a drug by another drug or withdrawal 
of a drug - no. (%) 
4 (1.0) 1 (0.4) 
Replacement of a drug by another drug or withdrawal 
of a drug prescribed “as required” - no. (%) 
13 (3.1) 0 (0.0) 
Replacement of a drug by another drug or to pause a 
drug therapy - no. (%) 
4 (1.0) 0 (0.0) 
Prescription of an additional drug - no. (%) 3 (0.7) 0 (0.0) 
Monitoring of the possible ADR - no. (%) 24 (5.7) 38 (14.7) 
Monitoring of the renal function - no. (%) 22 (5.3) 12 (4.6) 
Monitoring of the blood pressure - no. (%) 17 (4.1) 18 (7.0) 
Change of the drug application time - no. (%) 18 (4.5) 35 (13.6) 
Determination of the end of drug therapy - no. (%) 6 (1.4) 1 (0.4) 
Monitoring of the INR value - no. (%) 62 (14.8) 42 (16.3) 
Monitoring of the potassium serum level - no. (%) 77 (18.4) 39 (15.1) 
Monitoring of the drug blood or serum level - no. (%) 6 (1.4) 15 (5.8) 
Monitoring of the glucose blood level - no. (%) 24 (5.7) 6 (2.3) 
Verification of the indication - no. (%) 5 (1.2) 4 (1.6) 
Determination of the maximum dose - no. (%) 10 (2.4) 1 (0.4) 
Information provided about the pDDI only - no. (%) 70 (16.7) 11 (4.3) 
Others (< 1.0%) - no. (%) 6 (1.0) 6 (2.3) 
ADR = adverse drug reaction, INR = international normalized ratio, no. = number 
 
In 218 (38% of 567) cases of pDDIs during hospitalization and in 145 (37% of 392) 
instances of pDDIs at hospital discharge, no specific recommendation was provided 
by the pharmacist. In 148 (68% of 218) pDDIs during hospitalization and in 63  
(43% of 145) pDDIs at hospital discharge, the reason to ignore a recommendation 
was based on a different judgment of the clinical relevance of the DDI by the 
pharmacist. For example, the co-medication of insulin and cardioselective  
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beta-blockers, β2-sympathomimetics as inhalants and cardioselective beta-blockers, 
low molecular heparin and low dose aspirin or corticosteroids as inhalants and 
diuretics are all classified as moderate pDDIs by Pharmavista, but they were not 
assessed as clinically relevant by the pharmacist. Other reasons to ignore 
recommendations were due to individual patient variables (for example time-limited 
therapy, serum potassium level being too high or too low, prescription “as required”), 
or pDDI-management was already undertaken by the physicians. 
Acceptance of the interventions and assessment of the clinical relevance of potential 
drug-drug interactions by physicians 
80% (278 of 349) of the recommendations during the intervention period at 
hospitalization and 73% (180 of 247) of the recommendations during the intervention 
period at hospital discharge were accepted by the physicians. No feedback was 
obtained in 12% (42) and 13% (32), respectively. 8% (29) and 14% (35) of the 
recommendations, respectively, were not accepted. 
During hospitalization three recommendations concerning major pDDIs were not 
accepted. All three concerned a non-cardioselective beta-blocker and β2-sympatho-
mimetic as a local inhalant anti-asthmatic drug. 
At hospital discharge two recommendations concerning major pDDIs (a non-cardio-
selective beta-blocker combined with a β2-sympathomimetic as a local inhalant anti-
asthmatic drug and an α2-sympathomimetic drug combined with a beta-blocker) were 
not accepted. 
Out of 258 major and moderate pDDIs at hospital discharge 209 (81%) were 
assessed as clinically relevant by physicians, 15 (6%) as not clinically relevant and in 
34 (13%) pDDIs no feedback was obtained. Two major pDDIs (a non-cardioselective 
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beta-blocker combined with a β2-sympathomimetic as a local inhalant anti-asthmatic 
drug, and a potassium salt combined with a potassium-sparing diuretic) were 
assessed as clinically not relevant by the physician. 
Verification of physicians’ implementations 
Verification of the implementation was only possible in cases where drug regimen 
changes (withdrawal, replacement of a drug or prescription of an additional drug) 
were recommended. In the first part of the study (intervention period during 
hospitalization) 85% (60 of 71 reviewed cases) of the recommendations were 
accepted (no feedback 4, rejection 7). 47 recommendations were implemented 
during hospitalization, which correspond to 66% of all recommendations and 78% of 
instances, which were accepted. The second verification (intervention period at 
hospital discharge) revealed that two patients were deceased within one year after 
discharge and one patient changed his general practitioner and could not be located. 
In 85% (11 of 13 reviewed instances, which were accepted) the drug changes due to 
the recommendation were still substantive and the pDDI was still successfully 
cancelled one year after hospital discharge. 
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Summary of the pharmacist’s intervention and the physicians’ acceptance 
Figure I and II summarize the interventions and recommendations in major and 
moderate pDDIs by a pharmacist and the physicians’ feedback about the acceptance 
of the recommendations I) during hospitalization and II) at hospital discharge. We 
can assume that in 50% (during hospitalization) and 46% (at hospital discharge), 
respectively, of all detected major and moderate pDDIs by Pharmavista, intervention 
was accepted by the physicians. 
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Figure I: Pharmaceutical interventions to avoid major and moderate potential drug-drug interactions 
(pDDIs) during hospitalization and physicians’ acceptance of the recommendations 
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Figure II: Pharmaceutical interventions to avoid major and moderate potential drug-drug interactions 
(pDDIs) at hospital discharge and physicians’ acceptance of the recommendations 
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Discussion 
Interventions made by pharmacists might reduce prescribing errors [19-21]. 
According to Leape et al. the presence of a pharmacist on rounds in a medical 
intensive care unit was associated with a substantially lower rate of ADEs caused by 
prescribing errors. The rate of preventable ordering ADEs decreased by 66% from 
10.4 per 1’000 patient-days (95% CI 7 - 14) before the intervention to 3.5 (95% CI  
1 - 5) (p < 0.001) after the intervention [20]. Direct association among clinical 
pharmacy services, pharmacist staffing, and medication errors was shown by an 
evaluation of almost half a million medication errors in 1’081 United States hospitals 
[21]. An analysis of the causes of preventable prescribing errors revealed that 
pharmacists should play a key role in the defences against prescribing errors, and 
that they should provide a supply role and monitor prescriptions to detect any errors 
that arise [22]. Clinical pharmacist involvement is desirable in the prescribing process 
together with CPOE systems with advanced clinical decision support, because CPOE 
systems can mitigate most but not all prescribing errors [23]. Potential DDIs should 
be predicted and dealt with by close teamwork between physician and pharmacist at 
the moment medication is prescribed [24]. Despite these recommendations and 
findings, a recent study suggests that the medication reviews performed by a clinical 
pharmacologist with special knowledge of DDIs and ADRs does not necessarily 
reduce drug-related morbidity or mortality [25]. 
The acceptance of the recommendations by physicians in the present study  
(80% during the intervention period at hospital and 73% during the intervention 
period at discharge) was comparable to 63% reported in an intervention study, in 
which written advice was provided. Acceptance in more than 90% of interventions 
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was reported when direct spoken communication between physicians and 
pharmacists was possible [20, 26]. We assume that improvements regarding the 
acceptance of well-documented and easily manageable pDDIs would be possible. 
For example, three of 23 recommendations concerning interactions between statins 
and cytochrome P450 3A4 inhibiting drugs to replace the statin by a non-interacting 
statin or to pause the statin therapy during the anti-infectious therapy with 
clarithromycin were rejected by physicians. As reasons for these rejections they 
mentioned either absence of clinical relevance or rarity of clinical ADRs. To cite 
another example, three of eight recommendations concerning interactions between 
polyvalent cations and quinolone antibacterials to change the application time of the 
polyvalent cation were refused. 
The clinical management of pDDIs mostly implies monitoring of either symptoms of a 
possible ADR or laboratory parameters. Only in 11%, a modification of the 
prescription was recommended. These findings concur with the results of an analysis 
of the nature and management of DDI alerts in Dutch community pharmacies, where 
9% of all actions resulted in a modification of the prescription [27]. 
Drug interaction screening programs might be helpful tools to check prescriptions for 
DDIs. Although automated order checks offer possible benefits to patient care, the 
effect of such real-time warnings remains to be comprehensively assessed [28]. 
Previous research suggests that more warnings are ignored or overridden rather than 
followed [29, 30]. Diminishment of overrides was achieved by designating only critical 
to high-severity alerts [31]. About one third of all moderate pDDIs detected by 
Pharmavista were deemed to be not clinically relevant. This corresponds well with 
our evaluation study [18], which revealed a positive predictive value of 0.67 for 
Pharmavista using Stockley’s drug interactions [32] as a gold standard. Other 
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approaches to classify pDDIs not only according to the severity of a possible ADR 
might be more conducive to acceptance by physicians. An interesting assessment of 
DDIs was performed by a Netherlands working group [33] defining four core 
parameters: quality of evidence, clinical relevance, risk factors and incidence of the 
ADE. A management-orientated algorithm with four decision layers (severity, 
manageability, risk/benefit assessment and patient-related risk factors) was 
introduced and evaluated by another group [34]. Also the ORCA (OpeRational 
ClassificAtion) system takes into account the potential severity of the ADR due to a 
DDI, the factors known to increase or decrease the risk for an ADR and the existing 
management alternatives to avoid the DDI or to reduce the risk for an ADR by other 
means [35]. 
Hospitalized patients intervention can be provided at the point of prescription. In 
clinical practice DDI alert programs should be integrated into the CPOE system. 
Pharmacists should survey the overriding of alerts and interventions should be done, 
if overridden alerts are deemed clinically relevant [23, 26]. Drug prescription 
modifications shortly before hospital discharge are common. A pDDI check at 
discharge of the patients is substantial since the monitoring of patients after 
discharge becomes significantly restricted [10, 16]. 
Limitations 
Clinically manifest DDIs were not analyzed in this study and therefore we used the 
expression potential DDI. Data about negative clinical outcomes caused by DDIs are 
rare, but some retrospective studies have been published [36, 37] and showed 
increased risks for ADRs when drug prescriptions contain pDDIs. Intervention studies 
should be performed to investigate whether good clinical management of pDDIs can 
reduce drug-related morbidity or mortality. 
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Conclusion 
The management of clinically relevant pDDIs can be improved by physicians’ advice 
of clinical pharmacists. Changes in medication due to pDDIs were found to persist up 
to one year after hospital discharge. 
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Abstract 
Introduction 
Gastrointestinal (GI) bleeding is a frequent serious adverse drug reaction, potentially 
causing hospital admission and death. The aims of the present study were to 
investigate risk factors for a first-time GI bleeding leading to hospital admission and 
to assess the role of drug-drug interactions (DDIs) as a cause of GI bleeding. 
Methods 
We conducted a hospital-based case-control study at the Department of Internal 
Medicine at the Cantonal Hospital of Winterthur, Switzerland. 74 patients with a first-
time GI bleeding in 2005 were matched to 148 controls on age, sex and calendar 
time. Data were analyzed by univariate and multivariate conditional logistic 
regression with calculation of the odds ratios (ORs) and 95% confidence intervals 
(CIs). 
Results 
Univariate analyses showed an increased risk for first-time GI bleeding in patients 
with international normal ratio (INR) values ≥ 4 (OR 6.2, 95% CI 1.2 - 31.0), treatment 
with nonsteroidal antiinflammatory drugs (NSAIDs) (OR 7.0, 95% CI 2.8 - 17.2) and 
the combination of NSAIDs with glucocorticoids (OR 12.0, 95% CI 1.4 - 99.7). 
Anticoagulation alone in the therapeutic INR range was not associated with 
increased bleeding risk. Multivariate models including use of NSAIDs, oral 
anticoagulants, serotonin reuptake inhibitors (SSRIs) and/or proton pump inhibitors, 
body mass index, diabetes, hypertension and history of non-bleeding GI ulcer 
revealed a significant risk for GI bleeding for treatment with NSAIDs (OR 7.0,  
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95% CI 2.7 - 18.3) and with SSRIs in patients ≥ 70 years (OR 9.0, 95% CI 1.1 - 75.0). 
Increased relative risks for GI bleeding were found in multivariate analyses for 
combined use of NSAIDs and glucocorticoids (OR 10.5, 95% CI 1.2 - 94.4) and for 
combined use of oral anticoagulants and NSAIDs (8 cases, 0 controls). 
Conclusion 
The present findings suggest that a first-time GI bleeding is associated with INR 
values above the therapeutic range, but not with well-controlled oral anticoagulation 
in the absence of other risk factors such as DDIs. The combinations of 
glucocorticoids or oral anticoagulants with NSAIDs carry a high risk for GI bleeding 
and should therefore be performed only when the potential beneficial effects 
outweigh this risk. 
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Introduction 
Gastrointestinal (GI) bleeding is one of the most frequent serious adverse drug 
reaction (ADR) causing hospital admissions [1, 2]. According to Pirmohamed et al., 
drugs most commonly implicated in causing these admissions included diuretics 
(27.3%), aspirin (17.8%), nonsteroidal antiinflammatory drugs (NSAIDs) (11.8%) and 
warfarin (10.5%). GI bleeding was responsible for more than 50% of all ADRs leading 
to death [1]. Intake of anticoagulants is commonly recognized as a risk factor for 
bleeding complications. According to a nationwide study in The Netherlands the most 
frequent ADR-related diagnosis of hospital admissions was bleeding (8.6%), and the 
drugs most commonly associated with ADR-related hospitalizations were anti-
coagulants (17.8%) [2]. A Swiss study retrospectively analyzed all hospital 
admissions during one year and found that about 4% of them were directly related to 
ADRs. Analyzed by affected organ system, the most frequent ADRs were gastro-
intestinal complications (33%) caused by platelet aggregation inhibitors, NSAIDs, oral 
anticoagulants or digoxin. 21% of all ADRs were due to DDIs, whereof the 
combinations of NSAIDs and oral anticoagulants as well as the combination of 
platelet aggregation inhibitors and corticosteroids were most frequently observed [3]. 
Various former studies focused on the interaction between NSAIDs and oral 
anticoagulants as risk factor for GI bleeding. The short term risk for upper GI 
bleeding was six times higher (relative risk 5.8, 95% confidence interval (95% CI)  
2.3 - 13.6) when anticoagulated patients were exposed to NSAIDs compared with the 
use of anticoagulants alone [4]. According to Battistella et al., 0.3% of the 
anticoagulated patients (≥ 66 years) were hospitalized with upper GI bleeding per 
year, and the concomitant intake of NSAIDs was a risk factor for GI bleeding [5]. 
However, NSAIDs also seem to bear a risk for GI bleeding without concomitant 
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anticoagulant therapy. An observational cohort study showed that the relative risk of 
upper GI bleeding for elderly users (≥ 66 years) of non-selective NSAIDs was 4.0 
(95% CI 2.3 - 8.5) [6]. 
The aim of the present hospital-based case-control study was to investigate risk 
factors for a first-time GI bleeding leading to hospitalization with a special emphasis 
on the role of drugs and DDIs. 
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Methods 
Study population and data source 
The study has been reviewed and accepted by the local Ethics Committee. 
This retrospective hospital-based case-control study was conducted at the Cantonal 
Hospital of Winterthur, Switzerland, a 500-bed teaching hospital providing primary 
and secondary care to a population of approximately 200’000 inhabitants. Between 
January and December 2005, patients admitted to the Department of Medicine were 
eligible to be included into the study. 
Information on drugs prescribed at hospital admission (according to the anatomical 
therapeutical chemical (ATC) classification), demographic information (age and sex), 
admission date and length of hospital stay, main and additional diagnosis (according 
to the international classification of diseases, 10th revision (ICD-10)), body mass 
index (BMI), nutrition risk score (NRS) according to Kondrup et al. [7] and laboratory 
parameters (international normalized ratio (INR) value and helicobacter pylori  
(H. pylori) test) were obtained from the electronic patient records. 
Case definition and ascertainment 
Cases were defined as patients older than 18 years, who were hospitalized due to GI 
bleeding as the main diagnosis. Patients with the following computer-recorded 
diagnoses (ICD-10) were selected: K25.0, K25.2, K25.4, K25.6, K26.6, K27.0, K27.2, 
K27.4, K27.6, K28.0, K28.4, K28.6, K92.0, K92.1 and K92.2. By reviewing the 
hospital discharge letters, individuals with a history of GI bleeding prior to the current 
hospitalization were excluded. 
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Controls 
We identified at random two controls without current or previous GI bleeding per 
case, matched on age (± 1 year), sex and calendar time of hospital admission  
(± 1 month). 
Exposure definition 
Patients were defined as current users of a drug of interest, when – according to the 
medical history – they were under treatment at hospital admission. Intake of oral 
anticoagulants (ATC B01AA) was taken into account at least until two days before 
hospital admission. 
Analysis of drug-drug interactions 
Prescriptions at hospital admission were screened for DDIs potentially causing  
GI bleeding. As a result of our previous evaluation study of frequently used drug 
interaction screening programs [8], Pharmavista [9] was chosen to check 
prescriptions for DDIs. (The drug group of NSAIDs included both high- and low-dose 
aspirin). The program classified severities of DDIs into five categories: major, 
moderate, minor, insignificant or unidentified source. Major DDIs may be life-
threatening, or intoxication or permanent damage may be induced. Moderate DDIs 
frequently cause therapeutic difficulties, but the combinations may be administered if 
the patient is carefully monitored. DDIs of all severities and the combination of major 
and moderate DDIs were included in the statistical analysis (see below). 
Statistical analysis 
We conducted a matched analysis (conditional logistic regression model) using the 
software program SAS, version 8.02 (SAS Institute, Inc, Cary, NC). Relative risk 
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estimates (odds ratios (ORs)) are presented with 95% CIs. P-values less than 0.05 
were considered statistically significant. 
For each case and control, the effects of the following potential risk factors for GI 
bleeding were assessed in univariate conditional logistic regression models: BMI  
(< 25, 25 - 29.9, ≥ 30 kg/m2, or unknown), INR value (< 2, 2 - 3.9, ≥ 4, or unknown), 
NRS (< 3, ≥ 3, or unknown), drug use such as oral anticoagulants (ATC B01AA), 
phenprocoumon (B01AA04), acenocoumarol (B01AA07), NSAIDs (M01A), 
cyclooxygenase inhibitors (M01AH), proton pump inhibitors (PPIs) (A02BC) and 
selective serotonin reuptake inhibitors (SSRIs) (N06AB); the diagnoses diabetes 
(ICD-10 E10 - E14), hypertension (I10 - I15), obesity (E65 - E68), disorders of 
lipoprotein metabolism (E78), metabolic syndrome and history of non-bleeding  
GI ulcer were assessed. 
In a second step, we identified the DDIs of all severities and the DDIs classified as 
major or moderate in every patient and control, as well as specific DDIs between oral 
anticoagulants and SSRIs, NSAIDs, heparinoids, glucocorticoids, salicylates, 
tramadol or thrombocyte aggregation inhibitors, between heparinoids and salicylates, 
NSAIDs or glucocorticoids and between NSAIDs and thrombocyte aggregation 
inhibitors. 
We then applied two multivariate models: a “pharmacologic model” including the 
drugs ingested by patients and controls, and a “DDI model” including the DDIs 
identified as specified above. Both models were adjusted for confounders defined as 
variables showing a significant risk for GI bleeding according to the univariate 
analyses. In addition, analyses stratified by sex, age (< 70 years, ≥ 70 years) and 
localisation of the GI bleeding (upper and lower) were conducted. 
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Results 
Characteristics of the patients and dropouts 
During the study period from January to December 2005, the Cantonal Hospital of 
Winterthur registered 19’385 admissions, of which 24.3% (4’713) were allocated to 
the Department of Medicine, wherefrom 1.9% (90) due to GI bleeding as the main 
diagnosis. Sixteen cases were excluded (15 patients showed evidence for previous 
GI bleedings, one patient lacked sufficient clinical information). The detailed main 
diagnoses of the 74 cases are presented in Table I. 
Table I: Main diagnosis of cases with first-time gastrointestinal bleeding (n = 74) according to the 
international classification of diseases, 10th revision (ICD-10) 
Main diagnosis ICD-10 Number of cases 
(n = 74) (%) 
   
Gastric ulcer, acute with haemorrhage K25.0 1 (1.4) 
Gastric ulcer, chronic or unspecified with haemorrhage K25.4 18 (24.3) 
Gastric ulcer, chronic or unspecified with both 
haemorrhage and perforation 
K25.6 2 (2.7) 
Duodenal ulcer, acute with haemorrhage K26.0 2 (2.7) 
Duodenal ulcer, chronic or unspecified with haemorrhage K26.4 16 (21.6) 
Haematemesis K92.0 8 (10.8) 
Melaena K92.1 9 (12.2) 
Gastrointestinal haemorrhage, unspecified K92.2 18 (24.3) 
n = number of patients 
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Further characteristics of the cases and of the matched controls are displayed in 
Table II. During hospitalization, 4 (5.4%) cases and 13 (8.8%) controls died  
(p-value 0.34). 
Table II: Patient characteristics of cases with first-time gastrointestinal (GI) bleeding (n = 74) and 
controls (n = 148) 
  Number of cases 
(n = 74) (%) 
Number of controls 
(n = 148) (%) 
    
female 34 (45.9) 68 (45.9) Sex 
male 40 (54.1) 80 (54.1) 
< 40 2 (2.7) 4 (2.7) 
40 - 49 6 (8.1) 12 (8.1) 
50 - 59 7 (9.5) 13 (8.8) 
60 - 69 8 (10.8) 17 (11.5) 
Age 
≥ 70 51 (68.9) 102 (68.9) 
upper and lower 2 (2.7) 0 (0.0) 
upper 36 (48.6) 0 (0.0) 
lower 35 (47.3) 0 (0.0) 
Localisation of the 
GI bleeding 
not available 3 (4.1) 0 (0.0) 
Death during the hospitalization 4 (5.4) 13 (8.8) 
n = number of patients 
 
Univariate conditional logistic regression 
According to the univariate conditional logistic regression, we found a significantly 
increased risk for GI bleeding for various parameters: INR value ≥ 4 (OR 6.2, 95% CI 
1.2 - 31.0), hypertension (OR 2.4, 95% CI 1.0 - 5.4), NSAIDs (OR 7.0, 95% CI  
2.8 - 17.2), DDIs classified major or moderate (OR 3.3, 95% CI 1.5 - 7.2), pharmaco-
dynamic DDIs (OR 2.0, 95% CI 1.0 - 4.0) and DDIs between NSAIDs and 
glucocorticoids (OR 12.0, 95% CI 1.4 - 99.7). 
Furthermore, significant associations with GI bleeding were found for the following 
parameters in females: NSAIDs (OR 6.6, 95% CI 1.8 - 23.8), SSRIs (OR 6.0, 95% CI 
1.2 - 29.7) and interactions between NSAIDs and glucocorticoids (OR 12.0, 95% CI 
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1.4 - 99.7). Males had a significantly increased risk for GI bleeding when they had 
hypertension (OR 3.4, 95% CI 1.3 - 9.4), took NSAIDs (OR 7.3, 95% CI 2.0 - 26.3), 
or drug combinations resulting in pharmacodynamic DDIs (OR 4.5, 95% CI  
1.4 - 14.6). 
We further stratified by bleeding localisation. The risk for upper GI bleeding was 
significantly higher in patients with diabetes (OR 3.0, 95% CI 1.1 - 8.3), and when 
they took NSAIDs (OR 8.3, 95% CI 1.8 - 38.7). Bleeding localised in the lower GI 
tract was significantly associated with an INR value ≥ 4 (OR 6.8, 95% CI 1.3 - 34.8), 
use of NSAIDs (OR 6.3, 95% CI 2.1 - 19.3), all DDIs (OR 2.9, 95% CI 1.2 - 7.1), DDIs 
classified major or moderate (OR 3.7, 95% CI 1.4 - 9.9), pharmacokinetic DDIs 
(OR 5.0, 95% CI 1.6 - 15.9) and pharmacodynamic DDIs (OR 2.8, 95% CI 1.2 - 7.0). 
Patients ≥ 70 years showed a significantly increased risk for GI bleeding when they 
were exposed to NSAIDs (OR 6.6, 95% CI 2.5 - 18.0), to DDIs classified major or 
moderate (OR 4.1, 95% CI 1.6 - 10.9), to drug combinations resulting in pharmaco-
dynamic DDIs (OR 2.4, 95% CI 1.1 - 5.5), and when they took NSAIDs together with 
glucocorticoids (OR 10.0, 95% CI 1.2 - 85.6). 
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Multivariate conditional logistic regression 
We applied a “pharmacologic model” (Table III) analysing the influence of various 
drugs (NSAIDs, oral anticoagulants and SSRIs as main parameters) on GI bleeding. 
Parameters were adjusted for the main parameters given above as well as for the 
use of PPIs, for BMI, diabetes, hypertension and for history of non-bleeding GI ulcer. 
Use of NSAIDs only showed a significantly increased risk for hospital admission due 
to GI bleeding (adjusted OR 7.0, 95% CI 2.7 - 18.3). Within stratified analyses, 
patients aged ≥ 70 years were at a significantly increased risk for GI bleeding when 
they received SSRIs (adjusted OR 9.0, 95% CI 1.1 - 75.0). 
Table III: “Pharmacologic model” 
 unadjusted adjusted* 
 
Number of 
cases 
(n = 74) (%) 
Number of 
controls 
(n = 148) (%) OR (95% CI) p-value OR (95% CI) p-value 
       
NSAID 23 (31.1) 9 (6.1) 7.0 (2.8 - 17.2) < 0.01 7.0 (2.7 - 18.3) < 0.01 
Oral anticoagulant 14 (18.9) 24 (16.2) 1.2 (0.6 - 2.5) 0.61 0.7 (0.3 - 1.9) 0.54 
SSRI 6 (8.1) 5 (3.4) 2.4 (0.7 - 7.9) 0.15 3.2 (0.9 - 11.4) 0.08 
PPI 18 (24.3) 30 (20.3) 1.3 (0.7 - 2.5) 0.49 1.2 (0.5 - 2.7) 0.66 
BMI (≥ 30) 12 (16.2) 22 (14.9) 1.3 (0.6 - 2.2) 0.57 0.3 (0.0 - 1.6) 0.15 
Diabetes 17 (23.0) 25 (26.9) 1.5 (0.7 - 3.2) 0.26 1.5 (0.7 - 3.6) 0.33 
Hypertension 13 (17.6) 12 (8.1) 2.4 (1.0 - 5.4) 0.04 2.1 (0.8 - 5.8) 0.16 
History of non-
bleeding GI ulcer 
8 (10.8) 10 (6.8) 1.7 (0.6 - 4.3) 0.31 1.9 (0.6 - 6.1) 0.26 
*adjusted for NSAIDs, oral anticoagulants, SSRIs, PPIs, BMI, diabetes, hypertension and history of 
non-bleeding GI ulcer 
BMI = body mass index, 95% CI = 95% confidence interval, GI = gastrointestinal, n = number of 
patients, NSAID = nonsteroidal antiinflammatory drug, OR = odds ratio, PPI = proton pump inhibitor, 
SSRI = selective serotonin reuptake inhibitor 
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The “DDI model” (Table IV) evaluated the risk for GI bleeding due to DDIs classified 
as major or moderate, pharmacodynamic DDIs, pharmacokinetic DDIs and the DDI 
between NSAIDs and glucocorticoids. Parameters were adjusted for BMI, diabetes, 
hypertension and history of non-bleeding GI ulcer. Major and moderate DDIs were 
associated with a significantly increased risk for GI bleeding (adjusted OR 2.8,  
95% CI 1.2 - 6.4), and the combination of NSAIDs and glucocorticoids was also a 
significant risk factor (adjusted OR 10.5, 95% CI 1.2 - 94.4). 
Table IV: “Drug-drug interaction model” 
 unadjusted adjusted* 
 
Number of 
cases 
(n = 74) (%) 
Number of 
controls 
(n = 148) (%) OR (95% CI) p-value OR (95% CI) p-value 
       
Major and moderate 
DDIs 
17 (23.0) 11 (7.4) 3.3 (1.5 - 7.2) < 0.01 2.8 (1.2 - 6.4) 0.01 
Pharmacodynamic 
DDIs 
18 (24.3) 19 (12.8) 2.0 (1.0 - 4.0) 0.04 1.7 (0.8 - 3.5) 0.14 
Pharmacokinetic 
DDIs 
11 (14.9) 10 (6.8) 2.3 (0.9 - 5.6) 0.07 1.8 (0.7 - 4.6) 0.26 
DDI between NSAIDs 
and glucocorticoids 
6 (8.1) 1 (0.7) 12.0(1.4 - 99.7) 0.02 10.5 (1.2 - 94.4) 0.04 
*adjusted for BMI, diabetes, hypertension and history of non-bleeding GI ulcer 
BMI = body mass index, 95% CI = 95% confidence interval, DDI = drug-drug interaction, GI = gastro-
intestinal, n = number of patients, NSAID = nonsteroidal antiinflammatory drug, OR = odds ratio 
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Discussion 
Almost 2% of all admissions to the Department of Medicine at the Cantonal Hospital 
of Winterthur were due to GI bleeding. First-time GI bleeding was registered in 
slightly more male than female patients (54.1% vs 45.9%). The number of cases 
increased with age, more than two thirds of all patients admitted with first-time GI 
bleeding (68.9%) were at least 70 years old. 
Our study suggests that the risk for GI bleeding under treatment with oral anti-
coagulants alone was not elevated (adjusted OR 0.7, 95% CI 0.3 - 1.9), if the INR did 
not exceed 4, and if patients were not exposed to other risk factors. However, if the 
INR value was ≥ 4, an increased risk for GI bleeding was observed (OR adjusted for 
BMI, diabetes, hypertension and history of non-bleeding GI ulcer: 5.6, 95% CI  
1.0 - 30.3). This finding is in line with a recent Norwegian study reporting that 74% of 
patients treated with warfarin had – according to the authors – INR values above the 
therapeutic range at the time of GI bleeding [10]. According to a meta-analysis [11], 
the OR for major bleeds for INR 3 to 4 compared with INR 2 to 3 was 2.3 (95% CI  
0.5 - 10.1), and did not reach statistical significance. However, the OR for INR > 4 
compared with the INR 2 to 3 reference group was highly significant (OR 33.2,  
95% CI 9.1 - 121.1). Various studies showed that the safety management and 
monitoring of an oral anticoagulant therapy is a difficult challenge for both patients 
and physicians. In such studies, the INR values were beyond the therapeutic range in 
41 to 57% of the observation period [12-14]. 
Patients treated with NSAIDs showed a 7-fold risk (adjusted OR 7.0, 95% CI  
2.7 - 18.3) for hospitalization due to GI bleeding compared to patients without NSAID 
treatment. The results of two recent cohort studies showed a 3.6- and 5.5-fold higher 
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risk for current NSAID users of developing upper GI bleeding [15, 16]. According to 
another large case-control study the ORs ranged from 1.4 for aceclofenac to 24.7 for 
ketorolac, suggesting substantial differences between individual NSAIDs [17]. The 
annual incidence of NSAID-associated GI bleeding was also estimated in prospective 
outcome studies. Upper GI bleeding occurred in 3 to 4.5% of patients ingesting 
NSAIDs per year, and serious bleeding episodes due to bleeding of large blood 
vessel and/or gastric or intestinal perforation in approximately 1.5% [18]. 
In our study, patients treated with combined glucocorticoids and NSAIDs were 
exposed to an even 10-fold higher risk (adjusted OR 10.5, 95% CI 1.2 - 94.4) for GI 
bleeding. Similar results were published by Hallas et al. [15] (increase in risk from 5.5 
for patients using NSAIDs alone to 10 for patients using NSAIDs and gluco-
corticoids), by Mellemkjaer et al. [16] (increase in risk from 3.6 to 7.4), by Piper et al. 
[19] (increase in risk from 1.1 to 4.4) and by Weil et al. [20] (increase in risk from 3.8 
to 9.0). The combination of NSAIDs with oral anticoagulants is also associated with a 
higher risk of GI bleeding than use of NSAIDs alone. In the study of Mellemkjaer et 
al. [16], the risk for GI bleeding increased from 3.6 in NSAIDs users to 11.5 for the 
combination anticoagulants and NSAIDs. In a cohort study in NSAIDs users (≥ 65 
years), the risk for hospitalization due to a bleeding ulcer was 12.7-fold (95% CI 6.3 - 
25.7) for the combination anticoagulants and NSAIDs, and 4.0 (95% CI 3.4 - 4.8) for 
NSAIDs only [21]. In our study, eight patients were exposed to both NSAID and oral 
anticoagulants, but none in the control group, precluding the calculation of an OR. 
However, the OR for GI bleeding in patients treated with oral anticoagulants and 
NSAIDs compared to patients without these drugs is approximately 16. 
Potential major or moderate DDIs resulting in increased risk for GI bleeding were 
significantly associated with a three-fold risk for hospitalization due to GI bleeding 
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(adjusted OR 2.8, 95% CI 1.2 - 6.4). Gasse et al. conducted a nested case-control 
study to estimate the effect of concomitant use of potentially interacting drugs on the 
incidence of serious bleeding resulting in hospital admission or death. They 
calculated an adjusted OR of 3.4 (95% CI 1.4 - 8.5) in patients treated with warfarin 
and co-medication potentially increasing the effect of warfarin compared to warfarin  
alone [22]. 
The present results showed a significant association between age (≥ 70 years), 
treatment with SSRIs and hospitalization due to GI bleeding (adjusted OR 9.0,  
95% CI 1.1 - 75.0). Published clinical evidence on the relationship between SSRI use 
and GI bleeding is limited to observational studies. Two retrospective cohort studies 
found no association between SSRIs and any recent bleeding events [23, 24]. In 
contrast, two other retrospective observational studies found a relative risk for 
hospital admission due to GI bleeding in SSRI users compared to non-users of 3.6 
(95% CI 1.5 - 3.4) [25] and 3.0 (95% CI 2.1 - 4.4) [26], respectively. Van Walraven et 
al. analyzed three different groups of antidepressants that were classified as low, 
intermediate and high inhibition of serotonin reuptake. Their results showed a 
significant increase in upper GI bleeding with increasing inhibition of serotonin 
reuptake [27]. Moreover, available evidence suggests that concomitant use of SSRIs 
with NSAIDs or low-dose aspirin increases the risk for GI bleeding. In users of both 
medications, the risk markedly increased 12- to 15-fold and 5- to 7-fold as compared 
to nun-users of these drugs, respectively. The risk also increased 2.8-fold and  
1.7-fold, respectively, when compared with SSRIs alone [28]. 
We also analyzed concurrent illnesses such as diabetes, hypertension, obesity, 
disorders of lipoprotein metabolism and history of non-bleeding GI ulcer as risk 
factors for GI bleeding. Unadjusted conditional regression analyses showed 
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significant ORs for patients with hypertension (OR 2.4, 95% CI 1.0 - 5.5) or diabetes 
in male patients (OR 3.1, 95% CI 1.1 - 8.3). However, after adjusting for confounders, 
the statistical significance for both, hypertension (adjusted OR 2.1, 95% CI 0.8 - 5.8) 
and diabetes in male patients (adjusted OR 3.0, 95% CI 0.8 - 11.1) was lost due to a 
loss of power, but with very similar point estimates. The conclusion in a recent review 
supports these data, stating that hypertension may not be an independent risk factor 
for anticoagulant-related bleeding, when other risk factors were controlled for [29]. 
On the other hand, the presence of co-morbidities in patients with actual GI bleeding 
is associated with an increased mortality [30]. 
Limitations 
Any epidemiologic studies may be subject to limitations such as confounding. Our 
data were retrieved from electronic medical records, and therefore some laboratory 
parameters such as INR values and H. pylori tests lacked especially for control 
patients. In addition, possible misclassification of diagnoses and incomplete patient 
records has to be considered. Recent studies showed discrepancies of up to 40 to 
50% of patients’ medication by comparing medical records and patient-reported use 
of drugs [31-33]. For non-prescription NSAIDs, disagreement was found even in 74% 
of patients’ medication [33], and a systematic review found that up to 61% of patients 
had at least one omission error in prescription medication histories [34]. 
No statement about the GI bleeding risk for individual NSAIDs was possible in our 
study due to the small number of cases. A meta-analysis suggested that ibuprofen, 
followed by diclofenac bear the lowest risk for GI bleeding. Azapropazone, tolmetin, 
ketoprofen, and piroxicam ranked highest for risk where indometacin, naproxen, 
sulindac, and aspirin occupied intermediate positions [35]. According to a case-
control study, ketorolac was associated with the highest risk followed by piroxicam, 
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indometacin, ketoprofen and naproxen. Lower risks were found for aceclofenac, 
ibuprofen, nimesulide and diclofenac [17]. 
In our study, doses and durations of exposure to the drugs were not taken into 
consideration. In previous studies, increasing doses were shown to be a risk factor 
for upper GI bleeding [17] especially for ibuprofen and naproxen [16]. 
Finally, the number of cases (n = 74) and matched controls (n = 148) was rather 
small. 
Conclusion 
The results of this small hospital-based case-control analysis suggest that first-time 
GI bleeding is associated with high INR values, but not necessarily with oral 
anticoagulation alone if other risk factors such as DDIs are excluded. Although oral 
anticoagulants and NSAIDs as well as glucocorticoids and NSAIDs are frequently 
prescribed concomitantly in daily practice, our results emphasize the problems 
related to the combined use of these drugs. Strategies for reducing GI bleedings 
include better monitoring of INR values, careful dose adjustment and prescription of 
non-interacting drugs. 
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5 Conclusions 
Our studies highlight the importance of potential drug-drug interactions (pDDIs) as a 
contributing factor in drug safety. Improvements regarding the awareness of pDDIs 
and a strict management should be implemented. Prescribing drugs with a low risk 
for pDDIs as well as careful monitoring for adverse drug reactions (ADRs) are 
important measures in the prevention of harm associated with pDDIs. 
Drug interaction screening programs 
Drug interaction screening programs are helpful tools to check prescriptions for 
pDDIs. Although automated order checks offer possible benefits to patient care, the 
effect of such real-time warnings remains to be comprehensively assessed [1]. In 
agreement with previous research [2, 3], the quality of these programs should be 
assessed before the implementation of a drug interaction screening program. 
Our evaluation study of frequently used drug interaction screening programs showed 
that they vary not only in update frequencies, search and filter functions and severity 
classifications, but also regarding the quality of information provided within the 
interaction monographs and regarding the completeness and nomenclature of the 
drug list. Furthermore, sensitivity, specificity, positive and negative predictive value 
are of major importance. Pharmavista offers the most sophisticated information about 
DDI mechanism and clinical management, the highest sensitivity, a high negative 
predictive value and also an acceptable positive predictive value and can therefore 
be recommended. Our intervention study showed that one third of all moderate 
pDDIs detected by Pharmavista were deemed not to be clinically relevant. This 
corresponds well with the results of the evaluation study, which revealed a positive 
predictive value of 0.67 for Pharmavista. 
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Approaches not only including the severity classification of a possible ADR might be 
more acceptable by physicians. An interesting assessment of DDIs was performed 
by a Netherlands working group [4] defining four core parameters: quality of 
evidence, clinical relevance, risk factors and incidence of ADRs. A management-
orientated algorithm with four decision layers (severity, manageability, risk/benefit 
assessment and patient-related risk factors) was introduced and evaluated by Bergk 
et al. [5]. Also the OpeRational ClassificAtion (ORCA) system takes into account the 
potential severity of the ADR due to a DDI, the factors known to increase or decrease 
the risk for an ADR and the existing management alternatives to avoid the DDI or to 
reduce the risk for an ADR by other means [6]. 
Prevalence of potential drug-drug interactions and pharmacist interventions 
The main focus of this thesis was to elucidate the importance of clinically relevant 
pDDIs in the Medical Department of the Cantonal Hospital of Baden and to improve 
the clinical management of pDDIs by a pharmacist intervention during hospitalization 
and at hospital discharge. The analysis revealed that the quantity of prescribed drugs 
increased between hospital admission and patient discharge by 50%, but the number 
of major and moderate pDDIs per patient did not increase. In fact, the number of 
pDDI per drug pair administered was reduced by 50%. 47% of all major and 
moderate pDDIs at discharge were due to medication changes during hospitalization. 
Several deficiencies were detected regarding the management of clinically relevant 
pDDIs. 
In the following section, the goal was the improvement of the clinical management of 
pDDIs by means of pharmacist intervention. For hospitalized patients, 74% of all 
detected major and moderate pDDIs by Pharmavista were judged as clinically 
relevant by the pharmacist. 80% of the recommendations were accepted and 
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implemented by the physicians. During the intervention period at hospital discharge, 
66% of all major and moderate pDDIs were assessed as clinically relevant by the 
pharmacist, and 73% of the recommendations were accepted by the physicians. One 
year after hospital discharge, 85% of the drug changes due to the recommendations 
were still persistent. 
Overall, in 50% and 46%, respectively, of all major and moderate pDDIs detected by 
the drug interaction screening program Pharmavista a clinical management was 
provided by the physicians. It mostly implied a monitoring of either symptoms of a 
possible ADR or laboratory parameters. Only in 11 to 12% of the cases, a drug 
change was recommended. 
We assume that the management of clinically relevant pDDIs can be improved by 
physicians’ advice of clinical pharmacists. Changes in medication due to pDDIs are 
persistent even one year after hospital discharge. Clinical pharmacist involvement is 
desirable in the prescribing process together with computerized physician order entry 
(CPOE) systems with advanced clinical decision support, because CPOE systems 
can mitigate most but not all prescribing errors [12]. 
Potential drug-drug interactions as risk factors for gastrointestinal bleeding 
The last part of this thesis focused on a serious – and potentially drug-related – 
complication. Gastrointestinal (GI) bleeding is one of the most frequent and serious 
ADRs causing hospital admissions [13, 14]. According to Pirmohamed et al., GI 
bleeding was responsible for more then 50% of all ADRs leading to death [13]. Our 
results suggest that first-time GI bleeding is associated with international normalized 
ratio (INR) values above the therapeutic range, but not with well-controlled oral 
anticoagulation in the absence of other risk factors such as DDIs. Increased relative 
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risks for GI bleeding were found in multivariate analyses for combined use of NSAIDs 
and glucocorticoids and for combined use of oral anticoagulants and NSAIDs. 
Although oral anticoagulants and/or glucocorticoids are frequently prescribed 
concomitantly with NSAIDs, our results emphasize the hazard of these combinations 
and the need for rigid INR control. 
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